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Lyme disease is caused by an infection with the spirochete Borrelia burgdorferi.  
Transmitted between mammal reservoirs by the bite of an Ixodes tick, the pathogen exists 
in a complex life cycle that requires long-term persistence in arthropod and mammal 
hosts.  The mechanisms responsible for persistence and the pathogenesis of Lyme disease 
are not well understood, but may involve interactions between bacterial surface proteins 
and the host.  Previous experiments have shown that differential gene expression of 
surface proteins assists the pathogen in adaptation and persistence in a new host.  Most B. 
burgdorferi surface proteins have no homology to known proteins, making the 
identification of virulence factors difficult.  Gene expression analyses can be used to 
identify potentially important gene products for further study, based on the conditions 
under which they are expressed. 
To this end, the B. burgdorferi in vivo transcriptome of selected potential surface 
proteins was analyzed to identify promising targets for further study.  Based on these 




BBK07 were selected for further characterization.  My hypothesis is that these proteins 
are important for B. burgdorferi virulence and persistence in the murine host.  The 
surface exposure of each protein was assessed, as well as a detailed transcriptional profile 
of each gene.  Using specific antibody-mediated interference and gene inactivation, I 
show that neither BbCRASP-2 nor BBK07 is essential for infectivity or pathogenesis in 
the murine model of Lyme disease.  My results also indicate that BBK07 is a novel 
immunodominant antigen of B. burgdorferi that could be used as a serodiagnostic marker 
for human Lyme disease.  Using a peptide library, the most immunodominant epitopes of 
BBK07 were identified, and shown to improve the diagnostic accuracy over that of the 
full-length recombinant BBK07.  Finally, I show that BBK07-based diagnosis was 
sensitive even in the early stages of Lyme disease, and that the addition of BBK07 
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Chapter 1 - Introduction 
 
1.1 History and distribution of Lyme disease 
 
Lyme disease (LD), also known as Lyme borreliosis, is a potentially debilitating 
bacterial infection transmitted by ticks belonging to the Ixodes scapularis complex.  It is 
named for the city in which it was first recognized, Old Lyme, Connecticut.  Due to the 
unusual expanding skin lesion in patients and the tight geographic clustering of children 
suffering from arthritis, doctors at the Yale-New Haven Hospital identified LD as a 
distinct clinical entity in 1975 (Steere et al., 1977a).  The causative agent of LD, the 
spirochete Borrelia burgdorferi, was cultured from infected ticks in 1982, and the same 
organism was isolated later from patients with LD (Burgdorfer et al., 1982; Steere et al., 
1983).  Symptoms resembling LD were previously reported in Europe (Afzelius, 1921; 
Bannwarth, 1941), and later studies showed that mouse specimens collected in the United 
States in 1894 contained B. burgdorferi DNA (Marshall, Telford et al. 1994).  Recent 
phylogeographical analyses have suggested that B. burgdorferi was present in North 
America before the first European settlements (Hoen et al., 2009).  As the tools of 
molecular biology and understanding of the disease has progressed, the wide geographic 
range of Lyme disease has become apparent, and it is now recognized as the most 






The number of reported cases of LD continues to increase since the identification 
of the causative agent in the 1980’s (Bacon et al., 2008).  According to the Centers for 
Disease Control and Prevention (CDC), more than 20,000 new cases are reported 
annually in the United States, and in some counties the incidence is more than 500 cases 
per 100,000 individuals (Bacon et al., 2008).  The actual number of cases may be higher 
due to misdiagnoses because of the variability of clinical symptoms (Steere et al., 2004).  
Most cases in the United States occur in the northeast, mid-Atlantic and north-central 
regions (Bacon et al., 2008).  The forests of these regions are frequently inhabited by the 
Ixodes tick, the arthropod vector of B. burgdorferi (Dennis et al., 1998).  It is thought that 
the recent expansion of LD is due to the expansion of the Ixodes tick into areas of 
farmland that have reverted to forests since the mid-20th century (Chen et al., 2005).  LD 
remains an emerging infectious disease in many parts of the world (Piesman and Eisen, 
2008), and a continued human health threat to suburban and rural populations in the 
Northeast and Midwest United States. 
 
1.2 Clinical manifestations 
 
LD is a multi-system disorder that affects a variety of organs (Nadelman and 
Wormser, 1998).  Patients often experience a pathognomic skin rash at the start of the 
infection known as erythema migrans (Steere and Glickstein, 2004).  Another commonly 
observed symptom of disease is acute Lyme arthritis, a painful inflammation of the joint 
that occurs in 60% of untreated patients (Steere and Glickstein, 2004).  An infection of 




heart and associated tissues caused by the infiltration of neutrophils and macrophages 
(Duray, 1989).  The complications of carditis, while rare, can be severe, including 
complete atrioventricular block, acute myopericarditis, cardiomyopathy, and 
cardiomegaly (Steere et al., 1980; Lelovas et al., 2008).  Similarly, infection within the 
central nervous system can result in a complex neurological disorder called 
neuroborreliosis, reported in 3% of patients, that can be difficult to distinguish from more 
common disorders, leading some to conclude that it is underreported (Batinac et al., 
2006). 
 
Antibiotic treatment of LD is often successful in the early stages of disease 
(Steere and Glickstein, 2004).  When diagnosis is missed or delayed symptoms can 
become chronic, and in some cases resistant to antibiotic treatment (Steere and 
Glickstein, 2004).  Sensitive and specific diagnosis is a limiting factor in the 
improvement of LD treatment.  Only tick bites can expose patients to B. burgdorferi 
infection, but they can go unnoticed.  Up to 30% of patients do not display the erythema 
migrans rash indicative of LD, and instead require laboratory diagnosis to detect B. 
burgdorferi infection (Aguero-Rosenfeld et al., 2005).  The CDC currently recommends 
two-tiered serological testing for these patients (CDC, 1995).  If the patient’s serum is 
positive or equivocal in the first, more sensitive test, then it is tested in a more specific 
test to confirm the diagnosis (CDC, 1995).  The format of the first test is commonly an 
enzyme-linked immunosorbent assay (ELISA), while the second test is usually an 
immunoblotting assay (Aguero-Rosenfeld et al., 2005).  While many antigens have been 




none has demonstrated the sensitivity and specificity required to replace two-tiered 
serological testing (Aguero-Rosenfeld et al., 2005).  Research to improve diagnostic 
testing is ongoing, and the identification and characterization of new B. burgdorferi 
antigens is a central focus of LD research. 
 
1.3 Borrelia burgdorferi 
 
Lyme borreliosis is caused by many species of spirochetes from the genus 
Borrelia, broadly referred to as Borrelia burgdorferi sensu lato (Wang et al., 1997).  B. 
burgdorferi sensu stricto, hereafter referred to as B. burgdorferi, constituting several 
well-characterized and closely-related isolates, is the only B. burgdorferi sensu lato 
species known to cause disease in North America, while Borrelia garinii and Borrelia 
afzelii cause Lyme borreliosis in Europe and Asia.  In nature, B. burgdorferi exists 
primarily in rodent populations, transmitted between mammalians hosts by Ixodes ticks 
(Lane et al., 1991).  When an infected tick bites a rodent or other incidental hosts, 
including humans, B. burgdorferi is deposited in the skin.  The pathogen then 
disseminates throughout the host, preferentially colonizing the joint, heart, and skin 
tissues as well as central nervous system (Steere et al., 2004).  Wild mice do not appear to 
develop disease during B. burgdorferi infection, but some incidental hosts and laboratory 
mice mount a vigorous immune response against the pathogen, causing the symptoms of 








B. burgdorferi is an obligate parasite, highly evolved to exist in a specific 
ecological niche.  As such, its genome is not closely related to any other bacterium 
outside of the Borrelia genus (Fraser et al., 1997a).  The genome is highly segmented, 
containing a linear chromosome, as well as a large number of both linear and circular 
plasmid DNA elements (Casjens et al., 2000).  The largest replicon in the B. burgdorferi 
is referred to as the chromosome, but several of the plasmids appear to harbor essential 
genes, blurring the line between chromosomal and extrachromosomal elements 
(Labandeira-Rey and Skare, 2001; Byram et al., 2004; Jewett et al., 2007).  B. 
burgdorferi carries a relatively small genome of less than 2 million base pairs, which is 
less than half the genome size of Escherichia coli (Fraser et al., 1997a).  The small 
genome size is possible, in part, by host-provided nutrition that negates the need for many 
biosynthetic pathways.  B. burgdorferi lacks the ability to synthesize de novo all amino 
acids, nucleosides, and lipids, and relies on the host to provide these and other nutrients 
(Fraser et al., 1997a).  While encoding relatively few biosynthetic enzymes, B. 
burgdorferi likely encodes for a sophisticated array of membrane transport systems that 
assist in acquisition of metabolites from the remarkably diverse host and vector 
environments.  For example, compared to other bacteria, B. burgdorferi retains the largest 
percentage of phosphotransferase system permeases and encodes a large repertoire of 
peptide transporters (Saier and Paulsen, 2000).  Additionally, the borrelial outer 
membrane contains many differentially regulated outer surface proteins, presumably 




al., 2000).  Overall, the genomic structure shows B. burgdorferi to be a highly adapted 
bacterial pathogen. 
 
The chromosome is highly conserved among the spirochetes of B. burgdorferi 
sensu lato (Terekhova et al., 2006).  It is unique amongst bacteria, as it exists as a 
covalently closed linear DNA molecule, with each end containing hairpin telomeres 
(Casjens et al., 1997).  Genes that encode proteins appear to cover 93% of the 
chromosome’s sequence, 846 in all, with less than 11 psuedogenes among them (Fraser et 
al., 1997a).  Many chromosomal genes are clustered by function, and are transcribed as 
operons.  These operons include genes that are responsible for basic cellular functions, 
including DNA, RNA and protein synthesis, glycolysis, and cell wall synthesis (Fraser et 
al., 1997a).  The tightly packed, highly organized, and essential nature of many of the 
genes present on the chromosome indicate that the chromosome may be an evolutionarily 
stable replicon (Lynch, 2006).  B. burgdorferi relies on its chromosome to provide the 
bacterium with a stable set of the basic genes required for cell replication.  The 
chromosome’s stability stands in stark contrast to the plasmids of B. burgdorferi, relative 
hotbeds of recombination and evolution. 
 
B. burgdorferi contains as many as 23 plasmids, more than any other known 
bacterium.  There are at least 12 linear and 9 circular plasmids identified in the sequenced 
B31 M1 isolate (Fraser et al., 1997a), maintained at very low copy numbers, in the range 
of 1 or 2 copies per cell (Hinnebusch and Barbour, 1992).  While the chromosome is 




sequence varies widely among isolates (Terekhova et al., 2006).  Plasmids show 
increased genetic rearrangement when compared to the chromosome, as there are 
numerous paralogous sequences, putative psuedogenes, and noncoding DNA sequences 
(Fraser et al., 1997a; Casjens et al., 2000).  Bioinformatic analyses have shown that 
numerous recombination events have occurred among the plasmids, for reasons that are 
not yet understood (Casjens et al., 2000).  Recombination events could result in gene 
duplication, allowing mutations to accumulate on genes due to reduced selective 
pressure.  Only about 6 percent of genes located on plasmids have homologues outside 
the Borrelia genus.  Due to plasmid loss during B. burgdorferi replication, several studies 
have linked certain plasmids to mouse and tick infectivity (Schwan et al., 1988; Xu et al., 
1996; Purser and Norris, 2000; Stewart et al., 2005).  In addition, purported virulence 
factors such as VlsE and OspC are located on plasmids (Zhang et al., 1997; Pal et al., 
2004b).  B. burgdorferi encodes a vast array of surface lipoproteins on plasmids, an 
estimated 17% of plasmid genes (Fraser et al., 1997a; Casjens et al., 2000).  It appears 
that the more stable B. burgdorferi chromosome encodes most housekeeping functions, 





The structure of B. burgdorferi is highly adapted to survive and replicate in both 
the tick vector and vertebrate host.  The pathogen is a spirochete: a long, flat wave shaped 




surrounding a peptidoglycan-covered inner membrane (Barbour and Hayes, 1986; Charon 
et al., 2009).  Periplasmic flagella attach to each pole of the protoplasmic cylinder and 
wrap around the cylinder in a ribbon, imparting the flat wave morphology essential for 
motility (Motaleb et al., 2000; Charon et al., 2009).  Rotation of the flagella results in a 
wave propagated along the axis of the cell, propelling the spirochete forward (Goldstein 
et al., 1994).  This unique motility has been shown to be an order of magnitude faster 
than a neutrophil, the fastest cell in the human body, and allows movement through high 
viscosity fluids and penetration deep into tissues (Malawista and de Boisfleury Chevance, 
2008). 
 
The outer surface lacks lipopolysaccharide, unlike Gram-negative bacteria, and 
has a relatively low density of transmembrane proteins (Barbour and Hayes, 1986; 
Takayama et al., 1987).  B. burgdorferi boasts an unusually large array of lipoproteins, 
many of which are known to be exposed on the bacterial surface (Haake, 2000).  These 
proteins may serve to stabilize the outer membrane, in addition to other functional roles 
(Xu et al., 2008).  Since research thus far has not been able to demonstrate major toxic 
molecules secreted by B. burgdorferi, it is thought that surface lipoproteins have a major 
contribution to spirochete persistence, interacting with a variety host molecules to 
facilitate dissemination, tissue colonization, and immune evasion (Zhang et al., 1997; 
Kraiczy et al., 2001; Coburn et al., 2005).  Some lipoproteins have also been shown to be 
differentially expressed during the life cycle of the pathogen.  These observations have 




several promising vaccine candidates (Howe et al., 1986; Fuchs et al., 1992; Hanson et 
al., 1998). 
 
Surface lipoproteins are thought to be essential in several stages of the B. 
burgdorferi life cycle through interactions between the bacterial and host cell surfaces.  
The outer surface protein (Osp) family has been studied extensively for their contribution 
to virulence and persistence.  OspA, a surface exposed lipoprotein and a major 
constituent of the outer surface, has been demonstrated to mediate attachment to and 
escape from the tick gut, among other roles, such as tissue dissemination via plasminogen 
interaction and immune evasion in tick blood meal (Fuchs et al., 1994; Coleman et al., 
1997; Pal et al., 2004a; Battisti et al., 2008).  Another lipoprotein, OspC, has been shown 
to facilitate spirochete invasion of tick salivary glands (Pal et al., 2004b; Fingerle et al., 
2007) and establish murine infection (Grimm et al., 2004; Stewart et al., 2006; Tilly et 
al., 2007).  OspC also binds the tick salivary protein Salp15, an immune suppressor, to 
blunt the initial host immune response against B. burgdorferi (Ramamoorthi et al., 2005).  
A substantial portion of the linear plasmid lp28-1 encodes the essential lipoprotein VlsE 
and its fifteen vls recombination cassettes (Casjens et al., 2000).  During mammalian 
infection the sequence of the vlsE gene is altered by continual recombination with 
portions from randomly selected cassettes (Zhang et al., 1997; Coutte et al., 2009).  By 
altering the sequence of this surface antigen, it is thought that B. burgdorferi continually 
generates an ineffective humoral response, thereby evading adaptive immunity (Zhang et 
al., 1997).  Likewise, the surface protein Lmp1 has been shown to be essential in immune 




in immunocompetent mice (Yang et al., 2009).  A variety of lipoproteins cover the 
surface of B. burgdorferi, performing functions essential to the life cycle of the 
spirochete. 
 
1.3.3 Gene expression 
 
B. burgdorferi survives and proliferates in a number of diverse host environments.  
The unfed tick, the feeding tick, and the mammalian host each pose a new set of 
challenges to survival, including the host immune response, the available nutrients, and 
physiochemical parameters such as temperature and pH (Seshu et al., 2004; Clifton et al., 
2006; Hyde et al., 2007).  B. burgdorferi uses differential gene expression to adapt to 
these environments.  Microarray analyses have indicated that global gene expression 
changes occur in vitro when B. burgdorferi are exposed to conditions that mimic different 
stages of the pathogen’s life cycle (Ojaimi et al., 2002; Revel et al., 2002; Brooks et al., 
2003; Tokarz et al., 2004).  This has allowed researchers to more directly study gene 
regulation in the bacterium, albeit under artificial conditions.  It is thought that the 
alternative sigma factors RpoS and RpoN are involved in the large gene expression 
changes that occur during the transition between arthropod and mammal hosts (Elias et 
al., 2000; Hubner et al., 2001).  Few predicted transcriptional regulator proteins are 
encoded in the B. burgdorferi genome, including just two two-component systems 
(Fraser et al., 1997a).  However, research has shown that the pathogen is responsive to a 
variety of unconventional stimuli, including the host immune response (Fikrig et al., 




proteins with no known function suggest that novel gene regulation mechanisms could be 
at work.  While the mechanisms of gene regulation are not fully understood, the diverse 
microenvironments in which B. burgdorferi thrives highlights the importance of gene 
regulation in the life cycle of the pathogen. 
 
1.3.4 Genetic manipulation 
 
Tools for the manipulation of B. burgdorferi at the DNA level began to appear 
with the seminal development of selectable markers and B. burgdorferi transformation in 
1994 (Samuels et al., 1994).  New DNA can be introduced to B. burgdorferi via shuttle 
vectors or allelic exchange.  Shuttle vectors contain an origin of replication similar to that 
of B. burgdorferi plasmids, and can therefore be stably maintained in a B. burgdorferi 
isolate (Sartakova et al., 2000).  Site-directed mutagenesis of B. burgdorferi has also been 
accomplished through the use of recombinant DNA transformation.  Recombination 
events can be targeted by flanking a selectable marker on both sides with DNA sequences 
up- and downstream of the intended site.  During replication, a B. burgdorferi cell may 
use the recombinant DNA as a template and introduce new DNA into the genome of the 
cell via homologous recombination (Rosa et al., 2005).  Some recent studies have utilized 
transposon-mediated mutagenesis, useful in genome-wide screening, but this technique is 
not yet widely used in the mutagenesis of infectious isolates (Stewart et al., 2004; Botkin 





Shuttle vectors have been used in many experiments (Rosa et al., 2005), including 
the expression of foreign genes (Sartakova et al., 2000), restoration of a wild type copy of 
an inactivated gene (Hubner et al., 2001), overexpression of a particular gene (Strother et 
al., 2007), or the elimination of entire plasmids by introducing an incompatible origin of 
replication (Eggers et al., 2002).  Inserting DNA via allelic exchange is another powerful 
tool, as it can provide an opportunity to modify or delete existing DNA sequences.  
Homologous recombination has been used to inactivate genes (Yang et al., 2004), restore 
wild type copies of a gene (Revel et al., 2005), and insert inducible promoters to allow 
control of gene expression (Lenhart and Akins, 2010).  These studies are essential for the 
elucidation of individual gene function and will lead to a greater understanding of B. 
burgdorferi biology.  Overall, recently developed tools allow the genetic manipulation of 
B. burgdorferi, and may eventually map the essential genes for B. burgdorferi persistence 
and the pathogenesis of LD. 
 
1.4 Experimental mouse model 
 
 Several animal models of LD have been developed, including the use of mice, 
rats, hamsters, guinea pigs, rabbits and nonhuman primates (Philipp and Johnson, 1994).  
B. burgdorferi infection of C3H HeN mice constitutes a widely used experimental model 
for understanding LD pathogenesis.  It has been shown that all tested mice are susceptible 
to B. burgdorferi infection, but many develop only mild symptoms (Donahue et al., 1987; 
Barthold et al., 1990).  C3H mice have a mutation in Toll-like receptor 4, and are used 




et al., 1990).  These symptoms can mimic those seen in human patients, whether the 
infection begins via tick bite or syringe inoculation of in vitro-grown B. burgdorferi.  
Within the first week, the mice experience a mild bacteraemia with subsequent tissue 
colonization.  The clinical complications of arthritis, and carditis are apparent within a 
few weeks and spontaneously resolved after several months (Barthold et al., 1990).  
Tibiotarsal joint diameter is an effective means to quantify arthritis, and histochemical 
staining of joint and heart sections can be used to show the extend of inflammation (Pal et 
al., 2004b).  Quantitative polymerase chain reaction using infected mouse tissues is often 
used to measure the pathogen burden in particular tissues (Germer et al., 1999; Piesman 
et al., 2001).  Studies in mice have drastically enhanced our knowledge of B. burgdorferi, 
and were crucial in the development of the only Food and Drug Administration-approved 
human vaccine, as well as some diagnostic assays for LD (de Silva et al., 1996; Liang et 
al., 1999). 
 
1.5 Research objectives 
 
The main goal of this dissertation research is to better understand the 
pathogenesis and prevention of B. burgdorferi infection through the characterization 
of important surface proteins of unknown function.  Many of the unique abilities of 
the pathogen are likely imparted by functional surface proteins.  Although many such 
proteins are predicted by genomic sequence analysis, the roles of most surface proteins 
remain a mystery.  I believe that the techniques of molecular biology can be used to 




virulence and bacterial persistence.  Previous studies using cultured spirochetes have 
contributed much to our understanding of B. burgdorferi, but the microenvironments 
encountered by the pathogen in vivo are likely too complicated to be accurately 
reproduced in vitro.  Direct analyses of the in vivo transcriptome of B. burgdorferi will 
identify possible surface proteins that are transcribed during mammalian infection.  My 
major goals were to study the contribution of these surface proteins to microbial 
persistence and virulence.  To accomplish this, I used gene deletion and specific 
antibody-mediated interference in the laboratory model of LD.  Finally, the diagnostic 
utility of these proteins was assessed.  My overall hypothesis is that these proteins are 
important molecular tools of B. burgdorferi, and that their study will enhance our 












Borrelia burgdorferi, the bacterial pathogen of Lyme disease, differentially 
expresses select genes in vivo, likely contributing to microbial persistence and disease.  
The complex life cycle in which B. burgdorferi persists requires continuous adaptation to 
the changing environments of the arthropod vector and the mammal reservoir.  Studying 
the genes expressed in each environment can give an indication of the role of a particular 
gene product during the life cycle of B. burgdorferi.  Research on B. burgdorferi has 
failed thus far to identify major toxic molecules secreted by the pathogen.  This led me to 
theorize that important interactions that contribute to the development of LD may occur 
between host molecules and the proteins expressed on the B. burgdorferi cell surface.  To 
this end, I used a quantitative RT-PCR approach to compare a select portion spirochete 
transcriptomes in a variety of infected mouse tissues.  The transcription levels of genes 
encoding potential surface exposed proteins were assessed to identify genes that are 
expressed or induced during mammalian infection.  My results show that only a portion 
of these genes are transcribed at detectable levels, and that while many of these genes are 









Lyme disease (LD), caused by Borrelia burgdorferi sensu lato, is the most 
prevalent tick-borne human disease in the United States, Europe and many parts of Asia 
(Steere et al., 2004).  Once the pathogen is deposited in the mammalian dermis by 
feeding Ixodes ticks, it establishes a localized infection at the bite site, then disseminates 
to distant cutaneous sites and various internal organs, including the spleen, bladder, 
joints, heart and central nervous system (Barthold et al., 1990; Barthold et al., 1991; 
Steere et al., 2004).  While B. burgdorferi persists in several tissue locations in mammals, 
only a limited set of organs, most frequently the joints and the heart, experience robust 
host inflammatory responses resulting in clinical complications, such as Lyme arthritis 
and carditis.  Antibiotic treatment is usually, but not always, successful, and some 
patients develop a form of antibiotic-resistant arthritis that is thought to be unrelated to 
persistent infection (Radolf, 2005).  
  
The B. burgdorferi transcriptome undergoes dynamic changes during the complex 
enzootic cycle of the spirochetes (Liang et al., 2002; Narasimhan et al., 2002; Pal et al., 
2008a; Pal et al., 2008b).  B. burgdorferi grown in laboratory medium or within host-
implanted dialysis membrane chambers readily responds to altered environments, 
adapting to changes in temperature, pH, nutrients, and host immune responses (Schwan et 
al., 1995; Carroll et al., 1999; Narasimhan et al., 2002; Ojaimi et al., 2002; Revel et al., 




of the B. burgdorferi genome (8.6%), or 150 genes, could be differentially expressed in 
vitro in response to physiochemical alterations in growth conditions, and a major 
proportion of these genes (46%) encode proteins with predicted export signals (Revel et 
al., 2002).  However, while all B. burgdorferi lipoproteins have outer membrane export 
signals, some are retained in the periplasm by sequence-specific signals (Schulze and 
Zückert, 2006). 
  
The clinical complications of LD are primarily triggered by B. burgdorferi-
induced host inflammatory responses (Nadelman and Wormser, 1998; Steere and 
Glickstein, 2004; Connolly and Benach, 2005).  Although spirochetes colonize a wide 
variety of host tissues, the inflammatory response that results in pathology is observed in 
a limited set of host organs, most commonly in one or both mouse ankles or human knees 
and the heart.  The diversity of host niches likely influences spirochete gene expression.  
While microbial antigens that are expressed at higher levels in a tissue-specific manner 
may assist in B. burgdorferi persistence in local environments, antigens, especially those 
exposed on the microbial surface, could directly participate in host-pathogen interactions 
contributing to the genesis of organ-specific pathogenesis.  Therefore, I assessed the 
expression levels of a selected set of B. burgdorferi genes in diverse murine tissues 
because of their putative membrane localization.  The characterization of microbial 
ligands that are differentially expressed during the pathogen’s life cycle is important for 
the identification of novel vaccine targets and the prevention of the multi-system 





2.2 Materials and methods 
 
The identity and oligonucleotide primer sequences for the quantitative RT-PCR 
analysis of B. burgdorferi genes are indicated in Table 1.  The B. burgdorferi target genes 
(Fraser et al., 1997a; Casjens et al., 2000) were selected based on their predicted 
localization on the spirochete membrane according to the database annotation 
(www.tigr.org) and PSORT in silico analysis (Nakai and Horton, 2007).  Groups of mice 
(5 animals/group) were infected with B. burgdorferi (105 spirochetes/mouse), and 
samples of skin, heart, tibiotarsal joint and bladder were collected and frozen in liquid 
nitrogen at one-week intervals between 1 and 4 weeks of infection.  Total RNA was 
extracted from tissue samples using the TRIzol reagent (Invitrogen).  To reduce traces of 
contaminating DNA, samples were further digested with RNase-free DNaseI (Qiagen), 
purified using the RNeasy kit (Qiagen) and reverse transcribed to cDNA using the 
AffinityScript cDNA synthesis kit (Stratagene). 
 
The relative levels of B. burgdorferi cDNA in each sample was assessed by 
quantitative PCR (qPCR), and DNA contamination in each sample was measured using 
an equal volume of purified RNA as a template.  Samples from each time point were 
pooled by tissue type, and final pools of skin, heart, joints and bladder were used in the 
qPCR analysis.  The primers used for qPCR reaction were designed using OligoPerfect 
Primer design software (Invitrogen) based on the B. burgdorferi B31 M1 genomic 




annealing temperature (60ºC) and spanned 100-300 base pairs of each of the target B. 
burgdorferi genes.  Each primer pair was tested for efficiency and non-specific 
amplification by melt-curve analysis using B. burgdorferi genomic DNA as a template.  
In one case, where paralogous genes displayed extreme DNA homology, the same set of 
primers was assigned for the detection of both genes as indicated in Table 1. 
 
To generate reliable in vivo gene expression data and to further ensure specific 
amplification of B. burgdorferi cDNA in murine tissue samples, the qPCR amplification 
in each well was followed by melt-curve analysis, and wells showing non-specific 
amplification were discarded from data analysis.  The amplification cycle consisted of 
initial denaturation at 95°C for 5 min followed by 45 cycles each at 95°C for 10 sec, 
60°C for 20 sec and 72°C for 30 sec and final melt curve analysis: 55°C for 30 sec, 
increase 0.5°C per cycle to 95°C.  The amplification was performed in an iQ5 real-time 
thermal cycler (Bio-Rad) using SYBR Green Supermix (Bio-Rad).  For expression 
screening of B. burgdorferi genes, I simultaneously assayed 8 candidate genes in each 
96-well PCR plate using duplicate wells of template cDNA (skin, heart, joint and bladder 
samples) with parallel positive (B. burgdorferi genomic DNA) and negative (no template) 
controls.  Transcript levels of individual genes were assessed in spirochetes grown in 
vitro in BSK medium (107 cells/ml) and in each of the murine samples, calculated using 
the 2−ΔΔCt method (Livak and Schmittgen, 2001), normalized against flaB transcripts and 
presented as fold increase in gene expression.  Two independent mouse experiments used 








B. burgdorferi persists in diverse tissue environments of the mammalian host.  To 
identify B. burgdorferi genes that are expressed at high levels in vivo, particularly in a 
tissue-specific manner, I employed a sensitive quantitative RT-PCR (qRT-PCR) approach 
to compare spirochete transcriptomes in multiple murine tissues and in vitro.  A total of 
92 spirochete genes were selected for expression analysis, based on their putative 
association with the spirochete membrane as determined by the database annotation and 
in silico analyses for extracellular exposure (Table 1).  Two groups of C3H/HeN mice (5 
animals/group) were challenged with B. burgdorferi (105 cells/mouse) and skin, joints, 
heart and bladder tissue were collected following 1, 2, 3 and 4 weeks of infection.  Total 
RNA was isolated, and corresponding tissues from the indicated time points were 
combined into four separate pools of skin, joint, heart and bladder samples.  qRT-PCR 
analysis was performed using gene-specific primers.  Analysis of qRT-PCR data revealed 
that 44 B. burgdorferi genes (out of 92 assessed) were not transcribed at detectable levels 
in vivo.  The remaining 48 genes displayed variable expression across different tissues, 
presented as fold increase in transcript levels relative to flaB, together with corresponding 
in vitro expression levels (Fig. 1).  B. burgdorferi bb0210, annotated as surface-located 
membrane protein 1 (lmp1), which encodes an exported protein with type I signal peptide 
with unknown function (Fraser et al., 1997a), displayed the most dramatic differential 
expression in murine tissues, with the highest level of expression found in the heart (Fig. 
1). 
 
Figure 1.  Relative expression of selected B. burgdorferi genes. Total RNA was isolated from B. burgdorferi grown in vitro, and 
multiple tissues of infected mice.  RNA samples were pooled by tissue type and gene-specific transcripts were measured using qRT-
PCR. Fold increase in the expression of individual genes in each sample was calculated based on the 2−ΔΔCt method, normalized 








Putative Function or Gene 
Symbol 
 
Sequence (5′ → 3′: Forward, Reverse) 







































































































































































colicin V production GCCTGAGATTGCCTCAAGAC, 
GTGCATTAAAGGGGCGTAAA 
BB0785 










































HP, LP TTTGAGGCTAAAGGAGAGTTGG, 
CATTTCCCAAGGCAACAAAT 
BBD15 
HP, family 85, LP CAAGATAGATGGGGCTTCTCA, 
TTTGAAACATTAGATACTCTGGAAGAA 
BBE08 
HP, LP TTATTTTTGTGTTGATAAGTTCTTGC, 
GCATAAAAATACCTTTGCTTCTTTTT 
BBE19 
plasmid partition  AAAGGAGGTGTTGGCAAAAG, 
GGTTGATGCTTGTGGATCG 
BBG02 












OspD, LP AATGAAGGCGCAAATTCAAA, 
TTGCCTCATTTGATGCATTT 
BBK48 
P37, LP CGCCGATCAGGTTATAGACAA, 
CATATCGGGTTGCATGTCTG 
BBK07 
HP, LP CCTATTTCAAGGGCGTGAGC, 
TATGGCCATTGCTGCATTCT 






Rev, LP AAATGATTCTTCTGGAGGCAAA, 
TTGGCCGCTAATTTATCCTG 
BBN38 
ErpA, LP GTTTAAACGCTGGGGGACAT, 
ACGCAATATGTTCAGCACCA 
BBN39 
erpB2, LP GTGCTGTTTTTGCGCTGATA, 
TCGCCCTGCATTAATTCTTC 
BBO39 
ErpL, LP GCAAAGAAAAAGGGGGAGAG, 
TCACTGCCGCCATTAGAATA 
BBO40 
ErpM, LP GCAGGGCGATGATCCTAATA, 
GCTTTTGACTTTGCTTCTCCA 
BBP38 
ErpA, LP TGATGAGCAAAGCAATGGAG, 
GAATGTCCCCCAGCGTTTA 
BBQ05 






ErpX, LP GCAAGATTGATGCAACTGGT, 
TTTTTGCCAATTCATCTGCT 
BBS41 
OspG, LP CTTGCAAGATTGATGCGAGT, 
GGGTGTGTTATCGTGGGAAC 
BBS42 bapA TTGGACGCTCTTGAGGCTAT, 
GCAAATCAGCCAAAATTTGTT 
 
Abbreviations: CHP, conserved hypothetical protein; HP, hypothetical protein; LP, lipoprotein; 
IMP, inner membrane protein; MSP, membrane-spanning protein.  Designations of the open 









My overall goal is a better understanding of the Borrelia burgdorferi infection 
that causes LD.  SYBR Green qPCR has been used previously to study B. burgdorferi 
gene expression in infected mouse and tick tissues (Morrison et al., 1998).  In order to 
more efficiently target genes that encode surface-exposed proteins, I used a combination 
of database annotation and in silico analyses to select genes with possible surface 
localization (Nakai and Horton, 2007).  The study of gene expression at the level of 
transcription is by no means a perfect tool to assess the role of a gene-product in 
microbial pathogenesis.  For example, some genes associated with B. burgdorferi 
motility, an essential trait for infection and dissemination, appear to be constitutively 
expressed, and thus not necessarily carry specialized function to adapt spirochetes in 
specific host tissues.  However, if the pathogen has evolved to spend the energy required 
to preferentially upregulate a specific gene in a certain situation; it stands to reason that 
the protein expressed could play an important role in bacterial persistence. 
 
Of the screened genes, two were selected as promising for future study, based on 
additional evidence from the literature.  The first, bbh06, also known as Borrelia 
burgdorferi Complement Regulator-Acquiring Surface Protein 2 (BbCRASP-2), was 
among the transcriptionally active genes.  Previous studies have implicated BbCRASP-2 
in immune evasion by enhancing resistance to complement-mediated lysis (Hartmann et 




transcribed in vivo.  While previous work had demonstrated the immunogenicity of 
BBK07, the expression profile and functional role of the gene were unknown (Barbour et 
al., 2008).  The evidence from previous research, combined with the measured 
transcriptional profile led me to begin detailed studies of both genes for their contribution 
to persistence and genesis of disease.  As both are potential surface proteins, I therefore 
also evaluated the use of each as novel serodiagnostic markers for LD. 
 
In conclusion, these gene expression analyses of potential surface proteins have 
identified more than 40 genes that are transcribed during murine infection, including 
some that are induced in a tissue-specific manner.  These data also map the effects of 
tissue microenvironments on transcription, as each gene was assessed by tissue type.  The 
further characterization of microbial ligands that are differentially expressed during the 








A portion of this chapter has been published previously: 
Yang X, Coleman AS, Anguita J, Pal U (2009) A Chromosomally Encoded Virulence Factor Protects the 










Borrelia burgdorferi, the pathogen of Lyme disease, cycles in nature through 
Ixodes ticks and mammalian hosts.  At least five Complement Regulator-Acquiring 
Surface Proteins (BbCRASPs) are produced by B. burgdorferi, which are thought to 
assist spirochetes in host immune evasion.  Recent studies established that BbCRASP-2 
is preferentially expressed in mammals, and elicits a robust antibody response in infected 
hosts, including humans.  I show that BbCRASP-2 is ubiquitously expressed in diverse 
murine tissues, but not in ticks, reinforcing a role of BbCRASP-2 in conferring B. 
burgdorferi defense against persistent host immune threats, such as complement.  
BbCRASP-2 immunization, however, fails to protect mice from B. burgdorferi infection 
and does not modify disease, as reflected by the development of arthritis.  An infectious 
BbCRASP-2 mutant was generated, therefore, to examine the precise role of the gene 
product in spirochete infectivity.  Similar to the wild type B. burgdorferi, BbCRASP-2 
mutants remain insensitive to serum complement-mediated killing in vitro, retain full 
murine infectivity, and induce arthritis.  Quantitative RT-PCR assessment indicates that 
survivability of BbCRASP-2-deficient B. burgdorferi is not due to altered expression of 
other BbCRASPs.  Together, these results suggest that the function of a selectively 








Borrelia burgdorferi is the causative agent of Lyme disease (LD), the most 
prevalent vector-borne disease in the United States and Europe (Orloski et al., 2000; 
Steere et al., 2004).  In nature, B. burgdorferi cycles between rodent reservoirs and 
Ixodes scapularis ticks.  This complex enzootic life cycle requires successful colonization 
and coordinated transmission between strikingly different host and vector environments.  
It is thought that differential gene expression plays an important role in allowing the 
spirochete to navigate the transitions between hosts and in establishing persistent 
infection (de Silva and Fikrig, 1997; Schwan and Piesman, 2002; Rosa, 2005; Neelakanta 
et al., 2007).  Due to the availability of excellent murine models of Lyme disease, B. 
burgdorferi gene expression through the tick-rodent transmission cycle can be examined 
in the laboratory (Barthold et al., 1990; Schaible et al., 1991; Simon et al., 1991; 
Barthold, 1992; Barthold et al., 1993).  These efforts may provide important clues for 
understanding functions of microbial gene products that support B. burgdorferi 
persistence in nature (de Silva and Fikrig, 1997; Schwan and Piesman, 2002; Grimm et 
al., 2004; Rosa, 2005; Neelakanta et al., 2007; Pal et al., 2008b).   
 
The genes encoding the Complement Regulator-Acquiring Surface Proteins 
(BbCRASPs) of B. burgdorferi are differentially expressed in the pathogen life cycle 
(Hefty et al., 2001; Bykowski et al., 2007a).  As many as five BbCRASPs were identified 




spirochete defense against host complement-mediating killing (Alitalo et al., 2001; 
McDowell et al., 2003; Hartmann et al., 2006).  BbCRASP-1 (also known as cspA or 
bba68) and BbCRASP-2 (also called cspZ or bbh06), located on linear plasmids lp54 and 
lp28-3 respectively, share little sequence homology with other BbCRASP sequences.  In 
contrast, BbCRASP-3, -4 and -5 have similar sequences and belong to the erp paralog 
family and are known as erpP (bbn38), erpC and erpA (bbp38 and bbl39), respectively.  
Collectively these erp genes are also known as ospE, and are encoded on multiple cp32 
plasmids (Fraser et al., 1997a; Casjens et al., 2000; Kraiczy et al., 2004; Rogers and 
Marconi, 2007).  The gene erpC (located on cp32-2) and one of the three erpA genes 
(located on cp32-5) currently lack TIGR database annotations, as the sequenced B31 M1 
isolate lost these plasmids.  Of all the BbCRASP genes, BbCRASP-2 is the only gene 
without paralogous family members, and is therefore unique in B. burgdorferi (Hartmann 
et al., 2006). 
 
Evasion of host complement is especially important for B. burgdorferi, as it 
establishes an extracellular and disseminated infection in many tissue environments 
where the complement system is readily available through host vasculature or body 
fluids.  The complement system includes soluble membrane binding proteins which, upon 
contact with foreign cells, become activated, and are then capable of direct chemical lysis 
via membrane disruption (Medzhitov and Janeway, 2000; Medzhitov and Janeway, 
2002).  Specific regulatory proteins, such as FH family proteins, protect the host from 
self-inflicted damage by preventing unwarranted complement activation.  Pathogens such 




shown to bind host FH, and that FH binding in N. gonorrhoeae and B. burgdorferi 
provides protection against complement killing in vitro (Ram et al., 1998; Ram et al., 
1999; Jarva et al., 2002; Meri et al., 2002; Brooks et al., 2005). 
 
BbCRASPs have been identified according to their ability to bind proteins of the 
FH family, although individual BbCRASPs vary in their affinities for particular FH 
family proteins.  For example, only BbCRASP-1 and -2 preferentially bind factor H-like 
protein (FHL-1), while BbCRASP-3, -4 and -5 selectively bind factor H-related protein 
(FHR-1) (Hartmann et al., 2006; Haupt et al., 2007; Haupt et al., 2008).  BbCRASPs also 
vary in their interaction with uncharacterized serum proteins (Hovis et al., 2006; 
Bykowski et al., 2007a).  Though the binding affinities and the expression profiles of the 
BbCRASPs have been studied, the independent role of each BbCRASP in B. burgdorferi 
infectivity is not clear.  Recently studies using a non-infectious mutant demonstrated that 
the loss of BbCRASP-1 sensitized the B. burgdorferi to complement-mediated lysis in 
human serum, an effect that can be rescued with gene complementation (Brooks et al., 
2005).  While there is some disagreement as to the expression of BbCRASP-1 during 
mammalian infection, RT-PCR analysis indicate that it is only expressed transiently at 
the tick bite site and in ticks (Bykowski et al., 2007a), but not expressed in mice 
(McDowell et al., 2006).  BbCRASP-1 therefore, may not play an essential role in 
mammalian infection (McDowell et al., 2006), but could be important in spirochete 
survival in feeding ticks.  Although the above set of studies suggest an important role for 
BbCRASPs in spirochete immune evasion, the precise role of individual BbCRASPs, or 




infectious BbCRASP-deficient B. burgdorferi have not yet been successfully generated 
(Bykowski et al., 2007a). 
 
BbCRASP-2 is expressed by B. burgdorferi during murine infection (Bykowski et 
al., 2007a; Bykowski et al., 2007b), and infected hosts, including human patients, readily 
generate BbCRASP-2-specific antibodies (Hartmann et al., 2006; Kraiczy et al., 2008).  
This protein is conserved among B. burgdorferi isolates (Rogers and Marconi, 2007), 
reported to be localized on the spirochete surface (Hartmann et al., 2006) and has recently 
been suggested as a possible target for a second generation Lyme disease vaccine 
(Hartmann et al., 2006; Kraiczy et al., 2008).  The previous studies also suggest a 
possible functional role for BbCRASP-2 in immune evasion and pathogen survival 
(Hartmann et al., 2006; Rogers and Marconi, 2007).  In order to test this hypothesis, I 
sought to determine whether BbCRASP-2 is consistently produced in diverse murine 
tissues throughout the infection, and whether BbCRASP-2 immunization could provide 
host immunity and influence disease outcome.  To explore the precise role of BbCRASP-
2 in B. burgdorferi infectivity of a mammalian host, I assessed how targeted deletion of 
BbCRASP-2 in an infectious isolate influences B. burgdorferi infection in the murine 
model of LD.  Functional characterization of microbial ligands that are differentially 
expressed in the complex enzootic cycle of B. burgdorferi is critical to understanding the 
adaptive strategies of a pathogen that has evolved to persist in diverse tissue 






3.2 Materials and Methods 
 
Bacteria, Mice and Ticks.  Borrelia burgdorferi infectious isolate A3 (Elias et al., 
2002), a clonal derivative of B31 M1, was used throughout the study.  Female C3H/HeN 
mice between 4 and 6 weeks old purchased from the National Cancer Institute.  Mice 
were inoculated with a single subcutaneous injection of 105 spirochetes per mouse.  All 
animal procedures were in compliance with the guidelines set by the Institutional Animal 
Care and Use Committee.  The ticks used in this study belong to a colony that is reared 
and maintained in the laboratory as described (Pal et al., 2004a).   
 
PCR.  Mice were sacrificed following infection, and the heart, tibiotarsal joint, and skin 
samples were removed and frozen in liquid nitrogen.  B. burgdorferi-infected ticks were 
isolated by allowing ticks to feed on an infected murine host as described (Pal et al., 
2004a).  RNA was extracted using TRIzol reagent (Invitrogen) and further treated with 
DNase I (Invitrogen), and finally purified using the RNeasy kit (Qiagen).  RNA was used 
as a template for reverse-transcriptase polymerase chain reaction (RT-PCR) using the 
AffinityScript cDNA synthesis kit (Stratagene).  The primers used for PCR reactions are 
indicated in Table 2.  Quantitative PCR analysis was performed using iQ SybrGreen 
Supermix (BioRad) as previously described (Pal et al., 2008b).  For quantitative analysis 
of gene expression, the target transcripts were normalized to the number of flaB 




tissues, flaB transcripts were normalized to mouse or tick β-actin levels.  All quantitative 
PCR results were checked for specificity by melting curve analysis. 
 
Production of recombinant BbCRASP-2 protein and BbCRASP-2 antibodies.  
Recombinant BbCRASP-2 protein was produced in E. coli using the pET303/CT-His 
Champion vector (Invitrogen) using specific primers (Table 2).  Recombinant 
BbCRASP-2 was fused with a C-terminal 6-histidine tag for purification, and lacked the 
peptides encoding the lipidation signal.  Polyclonal antibodies against recombinant 
BbCRASP-2 were generated in mice as described earlier (Pal et al., 2004a; Pal et al., 
2008a).   Briefly, recombinant BbCRASP-2 (10 µg/animal) was emulsified in complete 
Freund's adjuvant (Sigma) and injected into groups of 10 mice.  The animals were 
boosted twice at 10 days intervals with the same dose of antigen in incomplete Freund's 
adjuvant (Sigma) and the sera were collected two weeks following the second boost.  
Titer and specificity of the serum was tested by ELISA and immunoblot blot as described 
previously (Pal et al., 2004b).   
 
Proteinase K accessibility assay.  Proteinase K accessibility assay were performed as 
described (Brooks et al., 2006).  Briefly, B. burgdorferi (2 x 108) were gently washed 
three times in 1 ml of PBS (pH 7.4) and collected by centrifugation at 4,000 x g for 4 
min.  Washed spirochetes were then gently resuspended in 1 ml of PBS and split into two 
equal 500 μl volumes.  One aliquot received 200 μg of proteinase K (PK) (Sigma 
Chemical Co.) while the other aliquot received an equal volume of PBS without PK.  




phenylmethylsulfonylfluoride (Sigma Chemical Co.) to stop PK activity.  Spirochete 
suspensions were subsequently pelleted by centrifugation at 10,000 x g for 10 min and 
resuspended in PBS for immunoblot analysis using antibodies against BbCRASP-2, FlaB, 
or OspA. 
 
Active immunization and infection studies.  Groups of mice (6 animals/group) were 
immunized with adjuvant containing either recombinant BbCRASP-2, or adjuvant 
containing the same volume of phosphate buffered saline (PBS) in similar fashion as 
describe in above paragraph.  Ten days after the final boost, mice were infected with a 
subcutaneous injection of B. burgdorferi (105 spirochetes/mouse).  Mice were sacrificed 
after 7, 12, 15 and 30 days of infection.  Heart, tibiotarsal joint, and skin samples were 
collected and frozen in liquid nitrogen.  RNA was isolated from infected tissues and B. 
burgdorferi burden was measured using quantitative PCR.  B. burgdorferi-infected mice 
were examined for swelling and histology of the tibiotarsal joints as detailed (Bolz et al., 
2004; Wang et al., 2005; Pal et al., 2008b).   
 
Generation and phenotypic analysis of BbCRASP-2 mutant.  BbCRASP-2-deficient 
B. burgdorferi was generated by homologous recombination replacing the entire open 
reading frame of the BbCRASP-2 gene with a kanamycin resistance cassette (Pal et al., 
2004b; Yang et al., 2004; Li et al., 2007b; Pal et al., 2008a; Pal et al., 2008b) using 
primers as indicated in Table 2.  DNA fragments flanking the BbCRASP-2 open reading 
frame on the 5′ and 3′ sides were PCR-amplified and inserted into the plasmid 




wild-type B. burgdorferi A3, and transformants were selected for growth in the presence 
of kanamycin.  PCR analysis was used to confirm the intended recombination event using 
primers P5-P12.  Immunoblotting analysis using BbCRASP-2 antibodies was performed 
to confirm the loss of BbCRASP-2.  The plasmid profile of the mutant B. burgdorferi 
was assessed to confirm no loss of wild type plasmids (Yang et al., 2004; Pal et al., 
2008a; Pal et al., 2008b).  
  
The serum sensitivity of the BbCRASP-2 mutant was measured using a published 
procedure (Alitalo et al., 2001).  Briefly, triplicate samples of wild type B. burgdorferi or 
isogenic BbCRASP-2 and BbCRASP-1 mutant (Brooks et al., 2005) were seeded into 1 
ml tubes at a final concentration of 5 x 106 bacteria per ml.  Spirochetes were 
subsequently incubated for different times with 50% normal human serum or 50% heat-
inactivated human serum.  At 0, 1, 4, and 16 hours after the addition of serum, samples 
were extracted and spirochete viability was examined using dark-field microscopy.  
Normal human serum (Sigma) collected from healthy, anonymous donors with no 
reactivity to B. burgdorferi after chemiluminescent immunoblot analyses were used in the 
assay. 
 
To examine the phenotype of the BbCRASP-2 mutant in vivo, the mutant and wild 
type B. burgdorferi were separately inoculated into 2 groups of mice (6 animals/group, 
105 spirochetes/mouse).  A skin sample, the heart and the joints from infected mice were 
isolated at day 7, 12 and 18 after challenge, and B. burgdorferi burdens were measured 




were cultured in BSK medium for the presence of viable B. burgdorferi.  Rear ankle 
joints of individual mice were measured before infection and at 7, 12 and 18 days after 
infection until sacrifice.  Acquisition of wild type and mutant B. burgdorferi by nymphal 
I. scapularis ticks was performed as described earlier (Pal et al., 2004a).  Briefly, groups 
of C3H mice (6 animals/group) were infected with wild type or BbCRASP-2 mutant B. 
burgdorferi (105 spirochetes/mouse).  Following 12 days of infection, 25 I. scapularis 
nymphs were placed on each mouse.  The ticks were forcibly detached from the mice 
following repletion and immediately stored in liquid nitrogen.  B. burgdorferi burdens in 
each tick sample were measured as described earlier by quantitative RT-PCR analysis. 
 
Statistical analysis.  Results are expressed as the mean ± standard error of the mean 
(SEM).  The significance of the difference between the mean values of the groups was 







BbCRASP-2 is ubiquitously expressed during murine infection.  To understand role of 
BbCRASP-2 in B. burgdorferi infectivity, I first assessed the transcript levels of 
BbCRASP-2 in multiple murine tissue locations where B. burgdorferi persists during 
infection, and in various stages of infected ticks.  C3H mice were infected with B. 
burgdorferi, and heart, joints and skin samples were collected at days 5, 7, 12, 16, and 24 
following infection.  Larval and nymphal ticks were fed on parallel groups of 15 day-
infected mice (25 ticks/mouse) and fully engorged ticks were isolated following 3 days of 
repletion.  Batches of infected fed larvae were allowed to molt and then collected as 
unfed nymphs.  Total RNA was prepared from murine and tick samples, and subjected to 
quantitative RT-PCR to measure the B. burgdorferi BbCRASP-2 transcript levels.   
BbCRASP-2 is ubiquitously and consistently expressed throughout infection (Fig. 2), but 






BbCRASP-2 immunization failed to evoke protective immunity in mice.  Because 
BbCRASP-2 is surface-exposed (Hartmann et al., 2006), immunogenic, and expressed 
throughout the murine infection, I next assessed if immunization of mice using 
recombinant BbCRASP-2 could elicit protective immunity and influence the outcome of 
Lyme disease.  To accomplish this, I produced recombinant BbCRASP-2 in E. coli and 
immunized the murine host with purified BbCRASP-2.  Separate groups of C3H mice (6 
animals/group) were immunized with either BbCRASP-2 or PBS (control) mixed with 
similar volume of adjuvant.  Immunoblotting performed after final boosting indicated that  
immunized mice had developed strong antibody titer that specifically recognized 
recombinant and native BbCRASP-2 (Fig. 3A).  Although previous immunofluorescence 
studies indicated that BbCRASP-2 antibodies recognized native antigen on the surface of 
 
Figure 2.  Ubiquitous expression of BbCRASP-2 in infected mice. 
The relative expression levels of BbCRASP-2 in the murine host, and in representative 
life stages of ticks, are analyzed and presented as copies of BbCRASP-2 transcript per 
1000 copies of flaB transcripts.  Total RNA was isolated from multiple tissues of B. 
burgdorferi-infected mice, from infected fed larva (FL) after 3 days of feeding, unfed 
nymphs following larval molting (UN) and fed nymphs (FN) after 3 days of feeding.  
BbCRASP-2 transcripts were measured using quantitative RT-PCR.  Bars represent the 




the intact spirochetes (Hartmann et al., 2006), the proteinase K accessibility assay 
indicated that BbCRASP-2 is not exposed on the spirochete surface (Fig. 3B).  Ten days 
after the final immunization mice were needle-inoculated with B. burgdorferi (105 
spirochetes/mouse).  B. burgdorferi levels were measured by quantitative PCR from skin, 
heart and joint samples collected at 7, 12, 15 and 30 days after infection.  Results 
indicated no significant difference in spirochete burden between mice immunized with 
BbCRASP-2 or the control at any time points (Fig. 4A).  These results indicated that 
BbCRASP-2 immunization did not influence the ability of B. burgdorferi to establish 
infection.  Development of ankle swelling (Fig. 4B) or histopathological changes in the 
joint tissue (data not shown) in B. burgdorferi-infected mice immunized with BbCRASP-
2 did not differ from the control, suggesting that host BbCRASP-2 antibodies fail to 
influence the ability of B. burgdorferi to induce arthritis in the murine host. 
 
 
Figure 3.  Characterization of BbCRASP-2 antisera and surface localization. 
(A) Recognition of recombinant and native BbCRASP-2 proteins by immunized 
murine serum, as assessed by immunoblotting.  Recombinant BbCRASP-2 protein 
or B. burgdorferi lysates were probed with BbCRASP-2 antiserum or normal mouse 
serum (NMS).  The arrow indicates the position of BbCRASP-2.  Migration of 
protein standards is shown to the left. 
(B) BbCRASP-2 is not sensitive to proteinase K-mediated degradation of B. 
burgdorferi surface proteins. Viable spirochetes were incubated with (+) or without 
(–) proteinase K for removal of protease sensitive surface proteins and probed with 
BbCRASP-2 antisera.  B. burgdorferi OspA and FlaB antibodies were utilized as 






Figure 4.  BbCRASP-2 immunization does not interfere with B. burgdorferi infectivity. 
(A) B. burgdorferi infection in rBbCRASP-2-immunized or control mice.  Groups of mice 
were immunized with either rBbCRASP-2 or PBS (control) mixed with adjuvant, and were 
infected with B. burgdorferi.  The spirochete burdens in both groups of mice were assessed 
by measuring copies of the B. burgdorferi flaB gene normalized to murine ß-actin.  Bars 
represent the mean measurements ± SEM from four quantitative PCR analyses from two 
independent infection experiments.  The burdens found in BbCRASP-2-immunized mice 
were not statistically significant from the control in any tissue or time point (P > 0.05, n = 4). 
(B) Severity of joint swelling in BbCRASP-2-immunized and infected mice.  Groups of mice 
(6 animals/group) were immunized with BbCRASP-2 (black bars) or PBS (control, white 
bars) and infected with B. burgdorferi.  Development of joint swelling was assessed after 12 
and 30 days of spirochete challenge by measuring the largest diameter of the rear 




Generation of an infectious isolate of BbCRASP-2-deficient B. burgdorferi.  Since 
BbCRASP-2 immunization did not influence spirochete infection, I created a BbCRASP-
2-deficient B. burgdorferi to more directly assess the role of the gene product in B. 
burgdorferi survival and infectivity.  An infectious isogenic mutant was created by 
replacing the BbCRASP-2 open reading frame with a kanamycin resistance cassette via 
homologous recombination (Fig. 5A).  PCR analysis was performed to ensure that the 
antibiotic cassette was appropriately inserted into the intended locus (Fig. 5B), and that 
the plasmid profile of the mutant was unchanged.  Out of 4 transformed clones that grew 
in antibiotic-containing media, 2 clones contained the desired integration of the antibiotic 
cassette and retained the same set of plasmid as in the parental isolate.  One of the mutant 
clones was chosen for further study.  RT-PCR analysis showed that BbCRASP-2 mRNA 
was absent in the mutant (Fig. 5C).  The BbCRASP-2 mutant spirochetes displayed a 
similar protein profile to that of the wild type (Fig. 5D, left panel), except that the 






BbCRASP-2 deficiency did not affected serum resistance of B. burgdorferi in vitro.  
B. burgdorferi is known to be resistant to complement-mediated lysis in serum, and 
deficiency of BbCRASP-1 has been shown to render B. burgdorferi highly susceptible to 
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Figure 5.  Construction and analysis of the BbCRASP-2 mutant B. burgdorferi. 
(A) Schematic drawings of the wild type isolate (WT) and the BbCRASP-2 mutant (M) at 
the BbCRASP-2 (bbh06) locus.  Genes bbh02-bbh09 (white box arrows) and the 
kanamycin-resistance cassette driven by the B. burgdorferi flaB promoter (flaB-Kan, black 
box arrow) are indicated.  Primers P1-P4 (black arrow-heads) amplified 5′ and 3′ arms for 
recombination, which were then ligated to either side of the flaB-Kan cassette. 
(B) Integration of the mutagenic construct, flab-Kan, in the intended genomic locus.  
Primers 5-12 (gray arrow-heads) were used for PCR analysis using  DNA isolated from 
wild type or BbCRASP-2 mutant B. burgdorferi. 
(C) RT-PCR analysis of BbCRASP-2 transcripts.  Total RNA was isolated from either the 
wild type or BbCRASP-2 mutant B. burgdorferi for RT-PCR amplification of regions within 
BbCRASP-2 and flaB, and these amplicons visualized on a gel. 
(D) Protein analysis of wild type (WT) or BbCRASP-2 mutant (M) B. burgdorferi.  Equal 
amounts of protein from wild type or BbCRASP-2 mutant spirochetes were separated on 
an SDS-PAGE gel, and either stained with coomassie blue (left panel) or transferred onto 
a nitrocellulose membrane and probed with BbCRASP-2 or FlaB antibodies.  Migration of 




serum-mediated killing in vitro (Brooks et al., 2005).  Because BbCRASP-2 is expressed 
by wild type spirochetes grown in culture, I assessed whether BbCRASP-2 deficiency 
affects the serum resistance of the spirochetes.  Equal concentrations of wild type and 
BbCRASP-2 mutant B. burgdorferi were separately incubated with human serum 
containing active complement and the serum sensitivity of each isolate was assessed.  
While the isogenic BbCRASP-1 mutant were readily killed within 1 hour of serum 
exposure, the viability of the BbCRASP-2 mutant did not differ significantly from that of 
the wild type (Fig. 6) indicating that BbCRASP-2 is not essential for B. burgdorferi 




1 .0 0 E + 0 0
1 .0 0 E + 0 1
1 .0 0 E + 0 2
1 .0 0 E + 0 3
1 .0 0 E + 0 4
1 .0 0 E + 0 5
1 .0 0 E + 0 6
1 .0 0 E + 0 7
1 .0 0 E + 0 8

































































Figure 6.  BbCRASP-2 mutant is resistant to complement-mediated killing in vitro. 
Triplicate wells of spirochetes were exposed to 50% normal human serum or 50% heat-
inactivated human serum (HI) and viability of B. burgdorferi was assessed using dark-
field microscopy.  An isogenic B. burgdorferi BbCRASP-1 mutant served as a serum-
sensitive positive control, which were killed within 1 hour of incubation with complement 
active serum as expected (P < 0.05, compared to corresponding HI control), while both 




BbCRASP-2-deficient B. burgdorferi retain full murine infectivity.  To examine 
whether the lack of BbCRASP-2 influences B. burgdorferi infectivity in a mammalian 
host, C3H mice were infected with wild type or BbCRASP-2 mutant B. burgdorferi.  Both 
the mutant and wild type spirochetes were readily cultured from ear and spleen tissues 
taken from mice 12 days after the inoculum.  When nymphal ticks were allowed to feed 
on infected mice, BbCRASP-2 mutant B. burgdorferi were able to migrate into fed ticks 
at a similar level to the wild type spirochetes (data not shown).  Quantitative RT-PCR 
further showed that the BbCRASP-2 mutant established infection in mice in comparable 
levels to the parental isolate.  No significant differences in the burdens of BbCRASP-2 
mutant and wild type isolates were detected in murine skin, heart and joint samples 
isolated after 7, 12 and 18 days of infection (Fig. 7).  Development of swelling in the 
murine joints infected with either the BbCRASP-2 mutant or the wild type B. burgdorferi 
was also similar (data not shown).  Overall, these results suggest that BbCRASP-2 is not 









Loss of BbCRASP-2 function is not compensated by augmented or new expression 
of other BbCRASPs.  BbCRASP-2 deficiency did not affect the ability of the BbCRASP-
2 mutant to survive complement-mediated lysis in vitro or establish infection in a 
mammalian host in vivo.  Since B. burgdorferi encodes multiple BbCRASPs that are 
capable of binding host complement regulators, I explored the possibility that the loss of 
BbCRASP-2 could be compensated by altered expression of other potential BbCRASP 
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Figure 7.  BbCRASP-2 mutant B. burgdorferi retain full pathogenicity in the murine 
host. 
Mice were infected with either the wild type or the BbCRASP-2 mutant B. burgdorferi and 
spirochete burdens were analyzed as before by measuring copies of B. burgdorferi flaB 
RNA normalized to murine ß-actin.  Bars represent the mean measurements ± SEM from 
four quantitative PCR measurements from two independent infection experiments.  No 
difference between wild type and BbCRASP-2 mutant levels was statistically significant in 




genes, such as BbCRASP-1, -3 and -5.  I did not examine the expression of BbCRASP-4, 
as the parental B. burgdorferi isolate A3(Elias et al., 2002) lacks the non-essential cp32-2 
plasmid housing the gene.  To examine BbCRASP expression, groups of 6 C3H mice 
were needle-inoculated with wild type or BbCRASP-2-deficient B. burgdorferi (105 
spirochetes/mouse).  Infected murine skin and heart samples were isolated 7, 12 and 18 
days after infection, and expression of each BbCRASP was measured by quantitative RT-
PCR.  In vitro expression of BbCRASP genes was also assessed by growing wild type and 
mutant B. burgdorferi in BSK medium to various cell densities (106 – 108 spirochetes/ml) 
and analyzed by quantitative RT-PCR.  The expression profiles of BbCRASP-1, -3, and -5 
remained unaltered in the BbCRASP-2 mutant when compared to the wild type 
spirochetes, both in vitro and in vivo, such as in the murine skin and heart tissues at all 
time points.  BbCRASP expression in cultured spirochetes grown in vitro to a density of 
107/ml and in infected murine skin and heart tissue samples at 12 days of infection is 
presented (Fig. 8).  These results suggest that the loss of BbCRASP-2 function is not 































































































Figure 8.  BbCRASP-2 inactivation does not affect the expression of other 
BbCRASP genes. 
The relative expression levels of BbCRASP-1, -2, -3 and -5 were examined in the 
BbCRASP-2 mutant and wild type spirochetes in vitro and in vivo by quantitative RT-PCR, 
and are represented as copies of gene per 1000 copies of flaB transcripts.  Total RNA 
was isolated from B. burgdorferi isolates grown in culture, as well as multiple tissues of B. 
burgdorferi-infected mice following 12 days of infection.  The experiments were replicated 
thrice, and bars represent the mean measurements ± SEM from four representative 
quantitative PCR measurements.  Differences between BbCRASP transcripts in the wild 




Table 2.  Oligonucleotide primers used in Chapter 3. 
 
Sequence (5’ to 3’) Purpose 
TTCAATCAGGTAACGGCACA 
Forward primer for B. burgdorferi flaB Quantitative RT-
PCR (qRT-PCR). 
GACGCTTGAGACCCTGAAAG Reverse primer for B. burgdorferi flaB qRT-PCR. 
AGAGGGAAATCGTGCGTGAC Forward primer for mouse β-actin qRT-PCR. 
CAATAGTGATGACCTGGCCGT Reverse primer for mouse β-actin qRT-PCR. 
TGCCAGACATGTTGCTGATT Forward primer for BbCRASP-2 qRT-PCR. 
CCCCCTCAAGTTCTACAGCA Reverse primer for BbCRASP-2 qRT-PCR. 
TTTCTAGAATGGATGTTAGTAGATTA
AATCAGA 
Forward primer for producing recombinant BbCRASP-
2.  The italicized XbaI site is included for cloning. 
ATACTCGAGTAATAAAGTTTGCTTAA
TAGCT 
Reverse primer for producing recombinant BbCRASP-
2.  The italicized XhoI site is included for cloning. 
AGAGAGAGGCGGCCGCAAACAACA
AAGACTCGCATATTCA 
Primer P1, used to amplify and clone the 5' flanking 
region to generate the BbCRASP-2 mutant.  The 
italicized NotI site is included for cloning purposes. 
GGACTGCAGGTTTCAATCTCTCTAA
ACATG 
Primer P2, used to amplify and clone the 5' flanking 
region to generate the BbCRASP-2 mutant.  The 
italicized PstI site is included for cloning purposes. 
AGGACTCGAGTTCATAGCCTCTAGC
ACAAG 
Primer P3, used to amplify and clone the 3' flanking 
region to generate the BbCRASP-2 mutant.  The 
italicized XhoI site is included for cloning purposes. 
AGGGGTACCATTTTGGAGTAGGGC
TAAA 
Primer P4, used to amplify and clone the 3' flanking 
region to generate the BbCRASP-2 mutant.  The 
italicized KpnI site is included for cloning purposes. 
TGCCAGACATGTTGCTGATT 
Primer P5, primer used to confirm the deletion of 
BbCRASP-2. 
CCCCCTCAAGTTCTACAGCA Primer P6, used to confirm BbCRASP-2 deletion. 
GGTTGCATTCGATTCCTGTT Primer P7, used to confirm BbCRASP-2 deletion. 
TGGAAATCCTCCATGGGAAA Primer P8, used to confirm BbCRASP-2 deletion. 
AATTCAATATGGAGGAAGTTTTAGG
GCT Primer P9, used to confirm BbCRASP-2 deletion. 
ATTCCGACTCGTCCAACATC Primer P10, used to confirm BbCRASP-2 deletion. 
TAAATGTATATGCTCCAGTAAACTAA
ACCAC Primer P11, used to confirm BbCRASP-2 deletion. 
CCTCAGGATGTCATATTGGTAGCA Primer P12, used to confirm BbCRASP-2 deletion. 
TCTTATTTACACACTAAACAACATTG
ACC Forward primer for B. burgdorferi bbh05 qRT-PCR. 
TAAACGCACGGCGTATAAAG Reverse primer for B. burgdorferi bbh05 qRT-PCR. 
TGATGAATTTTTGGGAATGTTTT Forward primer for B. burgdorferi bbh07 qRT-PCR. 
TGAATTTTATACATGGGTACAGTTTT
G Reverse primer for B. burgdorferi bbh07 qRT-PCR. 
CTAAAAGCAATTGGTAAGGAACTG Forward primer for BbCRASP-1 for qRT-PCR 
TCAATAAGATCGTAAGGACCAACT Reverse primer for BbCRASP-1 for qRT-PCR  
GTTTAAACGCTGGGGGACAT Forward primer for BbCRASP-3 for qRT-PCR. 
ACGCAATATGTTCAGCACCA Reverse primer for BbCRASP-3 for qRT-PCR. 
TGATGAGCAAAGTAGTGGT Forward primer for BbCRASP-5 for qRT-PCR. 






B. burgdorferi express up to five BbCRASPs that are either structurally unique, 
such as BbCRASP-1 and -2, or closely related, BbCRASP-3, -4 and -5 (Alitalo et al., 
2002; McDowell et al., 2003; Kraiczy et al., 2004; Hartmann et al., 2006).  These 
BbCRASPs are differentially expressed and are postulated to confer defense against host-
derived complements via specific interaction with FH family proteins (Alitalo et al., 
2001; Hartmann et al., 2006; Hovis et al., 2006; Haupt et al., 2008).  The precise role of 
individual BbCRASPs in the B. burgdorferi infection cycle, however, is currently 
unclear.  BbCRASP-2 is specifically produced in the mammalian host including humans, 
and is immunogenic, and thus, is thought to be important in spirochete pathogenesis and 
may be useful in a future Lyme disease vaccine (Hartmann et al., 2006; Kraiczy et al., 
2008).  Here, I show that BbCRASP-2 is ubiquitously expressed throughout murine 
infection, evoking a detectable antibody response.  However, BbCRASP-2 immunization 
fails to protect the host against B. burgdorferi infection or influence the genesis of 
disease.  Targeted deletion of BbCRASP-2 did not impair the ability of the mutants to 
resist serum-mediated killing in vitro, establish infectivity in vivo, or the severity of 
disease.  Deficiency of BbCRASP-2 expression in mutants is not functionally 
compensated by the enhanced expression of other BbCRASP genes.  BbCRASP-2, 
therefore, is not essential for B. burgdorferi survivability in vitro.  Furthermore, based on 
the time periods covered in the present study, BbCRASP-2 function is dispensable for B. 




Immunization of murine hosts against specific B. burgdorferi antigens, such as 
DbpA (Cassatt et al., 1998; Hanson et al., 1998), OspC (Probert and Lefebvre, 1994) and 
OspA (Fikrig et al., 1990) can elicit production of borreliacidal antibodies, and thus 
confer protective host immunity possibly by killing spirochetes in vivo when 
administered prior to spirochete infection.  In contrast, other B. burgdorferi antigens are 
also described, such as BmpA/B (Pal et al., 2008b) and Arp (Feng et al., 2000; Feng et 
al., 2003), that fail to protect host against B. burgdorferi infection, but influence 
pathogenesis either by reduction of the B. burgdorferi burden in selected tissues (Pal et 
al., 2008b) or by modifying the disease without affecting spirochete load (Feng et al., 
2000; Feng et al., 2003).  The failure of BbCRASP-2-specific host immunity to influence 
B. burgdorferi pathogenesis indicates that BbCRASP-2 antibodies lack significant 
neutralizing effects on spirochetes, possibly due to the lack of significant surface-
exposure of the antigen.  This is further confirmed by the observation that the BbCRASP-
2-deficient B. burgdorferi displayed no phenotypic defects in their ability to infect the 
murine host or induce disease.  Nevertheless, as BbCRASP-2 is abundantly produced by 
B. burgdorferi throughout infection and evokes development of specific antibody, these 
data reinforce an earlier contention that BbCRASP-2 could be a reliable marker for the 
serodiagnosis of Lyme disease (Hartmann et al., 2006; Kraiczy et al., 2008). 
 
B. burgdorferi expresses select lipoproteins (Casjens et al., 2000) in the 
mammalian host (Liang et al., 2002), including BbCRASP-2.  Owing to its ubiquitous 
expression in the host, and known affinity for FH family proteins (Hartmann et al., 2006), 




immune threats, such as complement system.  BbCRASP-2 is conserved among 
infectious B. burgdorferi isolates, which also suggests an important role for this protein 
in the infectivity of B. burgdorferi (Rogers and Marconi, 2007).  The plasmid lp28-3 that 
houses BbCRASP-2 is retained in most of the B. burgdorferi clones isolated from 
experimentally infected hosts (Purser and Norris, 2000; Labandeira-Rey and Skare, 2001; 
McDowell et al., 2001; Iyer et al., 2003).   Previous studies attempting to identify specific 
plasmids required for B. burgdorferi infectivity indicate that lp28-3 plasmid may not be 
strictly necessary for spirochete infectivity (McDowell et al., 2001) while other studies 
suggest that several plasmids, including lp28-3, in the correct combinations, may be 
required to mediate B. burgdorferi infection of the mammals (Labandeira-Rey and Skare, 
2001).  Nevertheless, these data conclusively show that the function of BbCRASP-2 is 
not essential for B. burgdorferi survival against serum-mediated killing in vitro or host 
infectivity.  The BbCRASP-2 mutant fails to produce both BbCRASP-1 and BbCRASP-2 
in the murine host, yet still retains full infectivity, which suggests that complement 
evasion in the host, if relevant, could be mediated by BbCRASP-3 and -5, which remain 
fully expressed by the mutant.  Alternatively, binding to certain FH family proteins may 
not be essential to the spirochetes, as previous studies indicate that B. burgdorferi are 
able to infect and cause disease in FH-deficient mice (Woodman et al., 2007).  
 
In summary, I present direct evidence that B. burgdorferi adapts for the loss of a 
differentially expressed and abundant lipoprotein during mammalian infection.  Past 
studies also identified additional B. burgdorferi genes encoding potential lipoproteins, 




Stewart et al., 2008) that display highly regulated expression in vivo but lack an essential 
role in B. burgdorferi persistence in tick-mouse infection cycle.  Here I show that 
BbCRASP-2 function is also dispensable for infectivity of the murine hosts or in feeding 
ticks.   Together, these results highlight B. burgdorferi as a unique pathogen that has 
evolved versatile adaptive strategies to survive and establish infection in a diverse array 
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Regulator-Acquiring Surface Protein 2 Does Not Contribute to Complement Resistance or Host Infectivity. 












The symptoms of Lyme disease are caused by infection with the spirochete 
pathogen Borrelia burgdorferi.  This bacterium is able to chronically infect mammals and 
evade host immune responses by unknown mechanisms that remain poorly understood.  
As many B. burgdorferi proteins have no homologues outside of the species with which 
to compare, the roles of individual genes are often investigated through genetic 
manipulation and specific antibody interference studies.  BBK07, a surface-exposed 
lipoprotein of B. burgdorferi, is selectively expressed during mammalian infection, and 
may have a function role in support of pathogen persistence and the genesis of disease.  
Here I show that BBK07 immunization of mice does not protect the host from B. 
burgdorferi infection or modulate the disease.  The bbk07 gene was then inactivated in an 
infectious isolate, showing that BBK07 plays a nonessential role in microbial infectivity 
and virulence in mice.  Together, these results suggest that the function of BBK07 is not 
necessary for the pathogenesis of Lyme disease.  Alternatively, it is possible that the 
function of BBK07 contributes to B. burgdorferi infectivity, but the loss of the gene 







The spirochete Borrelia burgdorferi, pathogen responsible for Lyme disease 
(LD), can be transmitted by Ixodes ticks and can chronically infect mammals (Steere et 
al., 2004).  Their complex life cycle has required unique adaptations, resulting in a highly 
specialized organism with only distant evolutionary links to other well-studied bacteria 
(Fraser et al., 1997a).  B. burgdorferi contains a stable and conserved linear chromosome, 
housing the basic functions required for replication (Fraser et al., 1997a).  In contrast, 
there are also around 23 plasmids of B. burgdorferi that show evidence of frequent 
recombination events.  Notably, more than 90% of the 419 plasmid-encoded open reading 
frames having no known function (Fraser et al., 1997a; Casjens et al., 2000).  Many of 
the unique abilities of B. burgdorferi could be contributed by these highly evolved 
plasmid-borne genes.  The identification and characterization of proteins critical to 
successful B. burgdorferi infection could lead to new diagnostic, preventive and 
therapeutic approaches to control incidences of LD. 
  
Previous studies have utilized mutagenesis, immunization, and repressible 
promoters to investigate the roles of individual B. burgdorferi genes in the life cycle of 
the bacterium(Rosa et al., 2005).  Due to the large number of low-copy number plasmids 
harbored by B. burgdorferi (Hinnebusch and Barbour, 1992), studies have also taken 
advantage of natural mutants that have lost one or more plasmids during replication to 




plasmid of B. burgdorferi that is rarely lost during in vitro culture (Jewett et al., 2007).  
An isolate lacking lp36 was found to be severely attenuated, a phenotype that could be 
rescued with the addition of the BBK17 gene, which encodes a putative adenine 
deaminase (Jewett et al., 2007).  The same degree of attenuation was not observed in an 
isogenic mutant lacking only the BBK17 gene, leading the authors to conclude that 
additional genes on lp36 might B. burgdorferi survival in mice (Jewett et al., 2007). 
 
A recent study used a synthetic protein array to detect antibodies in infected sera 
against B. burgdorferi antigens (Barbour et al., 2008).  Antibodies against BBK07, also 
located on lp36, were detected in both human and mouse sera (Barbour et al., 2008).  
Previous work also demonstrated that the bbk07 gene was transcribed throughout 
infection, and that an amino-terminal portion of the protein was exposed on the surface of 
B. burgdorferi (Coleman and Pal, 2009).  BBK07 protein was also suggested as a 
possible marker for the serodiagnosis of LD (Coleman and Pal, 2009).  The location of 
the bbk07 gene on the plasmid lp36, its expression during infection, and its surface 
exposure make it a promising candidate as a potentially important protein in B. 
burgdorferi.  In this study I have immunized mice with a recombinant fragment of 
BBK07 to assess whether BBK07 antibodies interfere with spirochete persistence in the 
host.  I then generated an isogenic mutant lacking the bbk07 gene, and using the 
laboratory model of LD, more directly studied the contribution of BBK07 to bacterial 





4.2 Materials and Methods 
 
Bacteria and mice.  The infectious Borrelia burgdorferi isolate A3 (Elias et al., 2002), a 
clonal derivative of B31 M1, was used in all experiments as wild type.  Female C3H/HeN 
mice between 4 and 6 weeks old were purchased from the National Cancer Institute, and 
all animal procedures were in compliance with the guidelines set by the Institutional 
Animal Care and Use Committee of the University of Maryland.  Mice were infected by 
intradermal inoculation of 105 spirochetes per mouse. 
 
Generation of bbk07 mutant B. burgdorferi.  The BBK07-deficient B. burgdorferi 
isolate was generated by homologous recombination, using methods and plasmids 
described previously (Pal et al., 2004b; Yang et al., 2004; Li et al., 2007b; Pal et al., 
2008a; Pal et al., 2008b).  Briefly, oligonucleotide primers P1-P4 (Table 3) were used to 
amplify regions up- and downstream of the bbk07 gene to serve as target DNA inserts 
required for allelic exchange.  These fragments were inserted on the plasmid pXLF10601 
into the two multiple cloning sites.  A streptomycin resistance cassette (aadA), driving by 
the B. burgdorferi flgB promoter was inserted between the fragments (Frank et al., 2003).  
This plasmid was used to electroporate B. burgdorferi cells, with recombination mutants 
selected by growth in the presence of streptomycin.  PCR analysis using primers P5-P11 
was used to confirm the desired recombination event.  Immunoblotting of wild type and 
mutant whole cell lysates were probed with anti-BBK07 sera, described in a previous 
study (Coleman and Pal, 2009).  Total RNA was isolated from wild type and mutant in 




converted to cDNA using the AffinityScript Multi Temperature First Strand Synthesis kit 
(Stratagene).  bbk07 transcription was assessed using the primers specific for the bbk07 
gene and for the positive control gene flaB listed in Table 3. 
 
Immunization experiments.  Groups of mice (3 per group) were immunized with a 
recombinant BBK07 fragment containing the amino terminal portion of the protein and 
excluding the signal peptide, amino acids 18-142 (Fraser et al., 1997a).  The protein was 
expressed using the pET302/NT-His Champion vector (Invitrogen) and purified using 
MagneHis nickel particles (Promega) according to the manufacturer’s instructions.  
Recombinant protein or phosphate buffered saline was emulsified in complete Freund’s 
adjuvant (Sigma) for the initial injection, and boosted twice emulsified in incomplete 
Freund’s adjuvant (Sigma) at 10 day intervals.  Ten days after final injection, mice were 
infected via intradermal needle inoculation of 105 spirochetes per mouse.  Heart, 
tibiotarsal joint, and skin tissue samples were collected at the indicated time points from 
euthanized mice and homogenized using a mortar and pestle under liquid nitrogen.  
Tissue homogenates were pooled by group and total RNA was extracted using TRIzol 
reagent (Invitrogen).  cDNA was synthesized using the AffinityScript Multi Temperature 
First Strand Synthesis kit (Stratagene).  Quantitative RT-PCR (qRT-PCR) analysis was 
performed using Roche SYBR Green and iQ5 thermal cycler as described (Yang et al., 
2009).  Primers for mouse β-actin and the B. burgdorferi gene flaB (Table 3) were used 
to quantitate the bacterial load using the 2-ΔΔCt method (Livak and Schmittgen, 2001).  





Mouse infection.  Groups of mice (3 per group) were infected with wild type or BBK07-
deficient B. burgdorferi.  To measure pathogen load during dissemination, 100 μl of 
blood was taken from each anesthetized mouse by retro-orbital bleed. Mice were 
sacrificed and the bacterial load measured as above.  Mouse tibiotarsal joint diameters 
were measured weekly using precision calipers. 
 
Statistical analysis.  Results are expressed as the mean ± standard error of the mean 
(SEM).  The significance of the difference between the mean values of the groups was 
evaluated by two-tailed Student t test.  Results were considered statistically significant if 







BBK07 immunization does not protect mice from B. burgdorferi infection.  Previous 
studies have indicated that BBK07 protein is expressed during infection, and that it is 
surface exposed and highly immunogenic (Coleman and Pal, 2009).  As these 
characteristics are ideal for effective vaccines against extracellular pathogens such as B. 
burgdorferi, I sought to evaluate possible vaccine efficacy of the BBK07 antigen.  
Expression and purification of a full-length recombinant BBK07 protein proved difficult 
in E. coli, as did a recombinant fragment encompassing the carboxyl-terminal half of the 
protein.  Instead, a recombinant protein fragment encompassing the amino-terminal half 
of BBK07 was purified as previously described (Coleman and Pal, 2009), and was used 
to immunize mice.  Previous research has shown that the amino-terminal half of BBK07 
is surface exposed (Coleman and Pal, 2009).  Immunizations were performed using 
Freund’s adjuvant, which successfully generated an efficient antibody response that could 
recognize BBK07 protein in B. burgdorferi lysate (Coleman and Pal, 2009).  Groups of 
mice were immunized with either BBK07 protein or buffer in an equal volume of 
adjuvant, and then infected intradermally with 105 B. burgdorferi per mouse.  B. 
burgdorferi could be cultured from bladder tissue from all mice sacrificed at 1 week post 
infection.  In order to measure the relative amounts of live B. burgdorferi in the samples, 
total RNA was isolated from tissue samples and the pathogen burden was measured by 
qRT-PCR (Fig 9).  Results show that BBK07 immunization did not significantly reduce 




there was no significant difference in arthritis, as measured by tibiotarsal joint diameter 
(data not shown). 
 
Mutagenesis of bbk07.  To more directly assess the role of BBK07 during infection, I 
inactivated the bbk07 gene in an infectious B. burgdorferi isolate by homologous 
recombination.  This method has been successfully used to inactive other genes in B. 
burgdorferi (Pal et al., 2004b; Yang et al., 2004; Li et al., 2007b; Pal et al., 2008a; Pal et 
al., 2008b).  Briefly, a plasmid containing the bbk07 locus and surrounding genes was 
constructed, with an antibiotic resistance cassette replacing a portion of the bbk07 gene.  
A double-crossover event using this plasmid as a recombination template inactivated the 
bbk07 gene (Fig. 10A).  PCR analysis confirmed that the antibiotic cassette had indeed 
recombined into the intended locus (Fig. 10B), and that the isolate had lost only the 



































Figure 9.  BBK07 immunization does not affect B. burgdorferi persistence in the 
murine host.  Mice (3 animals/group) were immunized with either purified BBK07N 
protein or an equal volume of PBS.  The immunizations were performed 3 times at 10 day 
intervals, first emulsified in CFA, and boosted twice in IFA.  The immunized mice were 
infected with B. burgdorferi (105 spirochetes/mouse) 10 days after the final booster 
immunization.  Total RNA was isolated from skin, heart, and joint tissue, and qRT-PCR 
was used to measure pathogen load in the tissue samples.  The bars represent the mean 




Labandeira-Rey and Skare, 2001).  RT-PCR analysis could not detect bbk07 gene 
expression in the mutant isolate (Fig 10C).  Anti-BBK07 sera generated previously 
(Coleman and Pal, 2009) was unable to detect BBK07 protein in the mutant isolate (Fig 
10D).  The insertion of the antibiotic cassette successfully inactivated transcription of the 









































Figure 10.  Generation of BBK07-deficient B. burgdorferi. 
(A) Schematic of wild type (Wt) and bbk07 mutant (Mut) B. burgdorferi sequences near 
the bbk07 locus.  The bbk07 gene (gray box arrow) was inactivated by homologous 
recombination with a plasmid containing a streptomycin resistance cassette (flgB-aadA, 
black box arrow) flanked by sequences up- and downstream of the bbk07 gene, 
amplified using primers P1-P4 (black arrowheads). 
(B) Analysis of bbk07 gene inactivation and surrounding genes.  DNA was isolated from 
wild type and bbk07 mutant B. burgdorferi and assessed by PCR with primers P5-P11. 
(C) RT-PCR analysis.  RNA was isolated from wild type and bbk07 mutant B. 
burgdorferi.  Primers specific to the gene flaB were used as a control, while bbk07 gene 
primers show that bbk07 RNA was only present in the wild type isolate. 
(D) Protein analysis of the wild type and bbk07 mutant.  Specific antibodies generated 
against BBK07 protein were used to probe lysates from wild type and bbk07 mutant 
isolates.  Ponceau staining (upper panel) shows equal protein loading, while the 




Inactivation of bbk07 does not affect persistence or virulence of B. burgdorferi in 
mice.  bbk07 gene inactivation was performed in a fully infectious B. burgdorferi isolate 
in order to study the role of BBK07 during infection.  It has been previously reported that 
the plasmid lp36, which contains the bbk07 gene, is nonessential for B. burgdorferi 
persistence in the tick vector but plays an important role during mammalian infection 
(Jewett et al., 2007).  Groups of mice were infected with either wild type or BBK07-
deficient B. burgdorferi by intradermal needle inoculation of 105 spirochetes per mouse.  
Bacterial load was measured in a blood sample taken 5 days after infection to measure 
hematogenous dissemination.  One and three weeks after infection the pathogen load was 
also measured in the heart, tibiotarsal joint, and skin.  Either wild type or mutant 
spirochetes were cultured from bladder, spleen, and skin samples from all mice sacrificed 
7 days after infection.  In order to measure the relative amounts of live B. burgdorferi in 
the samples, total RNA was isolated from tissue samples and the pathogen burden was 
measured by qRT-PCR (Fig. 11A).  To assess the severity of arthritis caused by the wild 
type and BBK07-deficient B. burgdorferi, the diameter of the tibiotarsal joints were 
measured weekly using a precision digital caliper (Fig. 11B).  Inactivation of the bbk07 
gene did not significantly affect bacterial load or severity of disease in two independent 
experiments.  Therefore, the inactivation of bbk07 did not significantly alter the 




























































Figure 11.  Inactivation of bbk07 does not affect spirochete persistence or disease 
in the murine host. 
(A) Mice (3 animals/time point) were infected with either wild type or bbk07 mutant B. 
burgdorferi and total RNA was isolated from blood, skin, heart, and joint samples.  
Pathogen load in each sample was assessed by qRT-PCR analysis of B. burgdorferi flaB 
normalized to murine β-actin using the 2-ΔΔCt method.  The bars represent the mean and 
SEM of 4 qRT-PCR reactions of two independent mouse experiments. 
(B) The severity of arthritis in the infected mice was assessed by measuring the largest 
diameter of the tibiotarsal joints with precision calipers.  The bars represent the mean and 




Table 3. Oligonucleotide primers used in Chapter 4. 
Sequence (5’ to 3’) Purpose 
TTCAATCAGGTAACGGCACA 
Forward primer for B. burgdorferi flaB Quantitative 
RT-PCR (qRT-PCR). 
GACGCTTGAGACCCTGAAAG Reverse primer for B. burgdorferi flaB qRT-PCR. 
AGAGGGAAATCGTGCGTGAC Forward primer for mouse β-actin qRT-PCR. 
CAATAGTGATGACCTGGCCGT Reverse primer for mouse β-actin qRT-PCR. 
AGAGAGAGGCGGCCGCTTTTTAAGCTC
TTCTTCAGAATA 
Primer P1, used to amplify and clone the 5' 
flanking region to generate the BBK07-deficient 




Primer P2, used to amplify and clone the 5' 
flanking region to generate the BBK07-deficient 




Primer P3, used to amplify and clone the 3' 
flanking region to generate the BBK07-deficient 




Primer P4, used to amplify and clone the 3' 
flanking region to generate the BBK07-deficient 
mutant.  The italicized KpnI site is included for 
cloning purposes. 
TAATTATTAAAGCACAAATGTATGGCC 
Primer P5, forward primer used to confirm the 
inactivation of the bbk07 gene. 
AGGAGGTGTTTACAAATGAGTAAACT 
Primer P6, reverse primer used to confirm the 
inactivation of the bbk07 gene. 
AGGCTGCAGCGAGCTTCAAGGAAGA 
Primer P7, forward primer used to confirm the 
inactivation of the bbk07 gene. 
AGGGCTAGCATTATTTGCCGACTACC 
Primer P8, reverse primer used to confirm the 
inactivation of the bbk07 gene. 
GCTTTCACTGTTTAGATGCATAAGGA 
Primer P9, forward primer used to confirm the 
inactivation of the bbk07 gene. 
TTGAGGTAAAATGGGGCAAA 
Primer P10, reverse primer used to confirm the 







The B. burgdorferi gene bbk07 is located on lp36, a plasmid known to contain 
genes that are essential and or thought to facilitate mammalian infection (Jewett et al., 
2007).  BBK07 protein has been shown to be expressed on the surface of the bacterium, 
and expressed during infection (Coleman and Pal, 2009).  In order to study its 
contribution to microbial persistence and disease, I have interfered with BBK07 function 
using two strategies.  First, the effects of specific antibody interference of BBK07, as 
well as the vaccine potential of BBK07, were tested by immunizing mice with a 
recombinant fragment of BBK07.  The mice were infected with B. burgdorferi and the 
protective immunity assessed.  Second, an infectious B. burgdorferi isolate deficient in 
BBK07 expression was generated to assess the role of BBK07 in spirochete infectivity 
and the pathogenesis of LD.  The effects of bbk07 gene inactivation and antibody 
interference were assessed using the murine laboratory model of LD.  Neither strategy 
had discernable effects on virulence or persistence, leading me to conclude that BBK07 is 
not essential for B. burgdorferi infection.  This could indicate, among other possibilities, 
that BBK07 function is redundant and is compensated by other proteins, or that the 
laboratory model of LD does not provide an opportunity to observe the true function of 
BBK07 in the B. burgdorferi life cycle. 
  
B. burgdorferi is an extracellular spirochete which is able to persist and 




ability to avoid immune clearance is not well understood, but may be due, in part, to 
antigen variation in the population.  Infection-induced genetic variation in the gene vlsE 
can potentially cause each spirochete to display a different VlsE on their surface.  
Heterogeneity in the sequences of outer surface proteins such as OspC and BmpA may 
also allow for a more diversified antigenic profile of the B. burgdorferi inoculum.  
Though possessing a relatively small genome, approximately 8% of genes are predicted 
to encode lipoproteins, a relatively large percentage when compared to other extracellular 
pathogens.  These lipid-modified proteins can anchor to the outer membrane and be 
surface exposed.  It has been previously shown that some genes are differentially 
regulated on a single cell level, with individual cells in the same population displaying a 
different surface protein profile. 
 
The abundance of lipoproteins encoded by the B. burgdorferi genome suggests a 
possible mechanism for enhancing humoral immune evasion.  B. burgdorferi could have 
a large repertoire of surface proteins, including the lipoprotein BBK07, that are 
differentially expressed by the spirochete population in order to increase the chances of 
surviving the immune response.  A large enough family of surface proteins could allow 
the inactivation of one or several genes without discernable effect in the murine 
laboratory model.  Functionally redundant protein families in B. burgdorferi could 
explain the myriad of experiments that have reported little to no effects after gene 
deletion experiments, including BbCRASP-2 (Coleman et al., 2008), BBK32 (Li et al., 
2006), OspD (Li et al., 2007a; Stewart et al., 2008), LuxS (Hubner et al., 2003), ChbC 




BBK07 is indeed important for B. burgdorferi to persist in the murine host, but that the 
laboratory model of LD does not provide an opportunity to study the true function of 
BBK07.  While inbred mice, such as the C3H mice used in these studies, display many of 
the same symptoms that are common in human LD, wild mice such as Peromyscus 
leucopus are not susceptible to disease, and act as the natural reservoir for B. burgdorferi.  
Future studies are required to assess the possibility that BBK07 provides a selective 
advantage towards persistence in wild mice. 
 
Though the lipoprotein BBK07 is expressed during infection, is immunogenic, 
and is surface exposed, these data show that immunization with surface exposed amino-
terminal half of BBK07 does not interfere with pathogen persistence in the laboratory 
model of LD.  As a result, vaccination with the BBK07 fragment also does not modulate 
the severity of disease.  Furthermore, an isogenic mutant lacking BBK07 was 
indistinguishable from wild type B. burgdorferi during murine infection.  In conclusion, 
these current data suggest that the lipoprotein BBK07 is a nonessential for mouse 











Lyme disease (LD) is a common tick-borne infection caused by the bacterial 
pathogen Borrelia burgdorferi.  Current laboratory diagnostic tests mostly use borrelial 
lysates, as well as recombinant and synthetic antigens to detect serum antibodies against 
B. burgdorferi as an indicator of infection.  These immunoassays are not entirely 
effective to detect the infection, especially in the early stages of disease.  BBK07, a novel 
lipoprotein of B. burgdorferi, is evaluated as a potential serodiagnostic marker of LD.  I 
show that the bbk07 gene is expressed at extremely low levels in vitro and in ticks, but is 
dramatically induced by spirochetes once introduced into the host, and is highly 
expressed throughout mammalian infection.  In contrast, the expression of bbk12, a 
paralog of bbk07 with 87% amino acid identity, although expressed in vitro, remained 
undetectable in vivo throughout murine infection and in ticks.  BBK07 is localized in the 
outer membrane and the amino-terminal domain of the antigen is exposed on the 
microbial surface.  A truncated BBK07 protein representing the amino-terminal domain 
is able to effectively detect antibodies to B. burgdorferi, both in experimentally infected 
mice and in humans.  I show that BBK07-based detection is not only sensitive but also 
highly specific against B. burgdorferi infection in human patients from North America.  
Using an overlapping peptide library of the full-length BBK07 antigen, I identified the 




show that a select combination of immunogenic peptides housed in the amino-terminal 
region of the protein significantly enhanced BBK07-based diagnostic accuracy when 
compared to the full-length recombinant protein.  An independent serum panel collected 
from LD patients in the early stages of disease was tested using the BBK07 peptide 
combination, as well as previously established B. burgdorferi serodiagnostic peptides: 
VlsE-derived C6 and OspC-derived pepC10.  While BBK07 peptides had a lower overall 
sensitivity than the C6 or pepC10 peptides, as determined by IgG or IgM ELISA, 
respectively, a subset of samples highly reactive to BBK07 peptides failed to recognize 
either VlsE or OspC peptides.  This suggests that BBK07 peptides could be useful to 
complement the efficacy of current C6 and pepC10-based serodiagnostic assays.  Finally, 
using a panel of canine sera, I show that BBK07 peptide-based serodiagnosis is highly 
effective for LD diagnosis in infected dogs.  Together, these data show that peptides from 
the B. burgdorferi surface protein BBK07 are highly specific and sensitive serodiagnostic 








Since the identification of Borrelia burgdorferi as the causative agent of Lyme 
disease (LD) over 25 years ago the number of reported cases of LD has increased steadily 
(Steere et al., 1977b; Bacon et al., 2008).  Every year more than 20,000 patients are 
diagnosed in the United States, and an estimated 2 million LD serological tests are 
performed (Aguero-Rosenfeld et al., 1993; Bacon et al., 2008).  Difficulties in diagnosis 
have long complicated the treatment of LD, as the bite of an infected tick may go 
unnoticed by the patient, and the clinical manifestations of LD can significantly vary 
amongst diagnosed patients (Steere et al., 2004).  Common symptoms such as fever, 
malaise, and arthritis can resemble those caused by other conditions, further complicating 
diagnosis.  Antibiotic therapy is highly effective, especially if administered in the early 
stages of LD, however, serious complications can result from false diagnoses and 
inappropriate treatment (Steere et al., 1993; Ettestad et al., 1995; Tugwell et al., 1997; 
Brown et al., 1999; Patel et al., 2000).  There is no commercially available vaccine for 
human LD, so the development of accurate, sensitive laboratory diagnostics is an 
important goal of LD research. 
 
 While many laboratory methods have been used to assess B. burgdorferi 
infection, direct detection of the bacterium is difficult due to the low pathogen load in 
clinical samples (Johnston et al., 1985; Aguero-Rosenfeld et al., 2005).  Likewise, the 
extremely slow growth of B. burgdorferi, the high cost and the labor-intensive procedure 




tool (Nadelman and Wormser, 1998; Stanek and Strle, 2003).  PCR detection is possible 
(Schwartz et al., 1992), but not widely used for diagnosis, due primarily to low sensitivity 
in tissues, such as cerebrospinal fluid and blood (Aguero-Rosenfeld et al., 2005).  Instead, 
seroreactivity is currently the primary method of laboratory diagnosis of LD (Aguero-
Rosenfeld et al., 2005).  If the patient does not present erythema migrans, a 
pathognomonic skin rash, a two-tiered serological approach for LD diagnosis has been 
recommended by the Centers for Disease Control (CDC, 1995).  A tested serum that is 
considered positive or equivocal by a sensitive method, most commonly enzyme-linked 
immunosorbent assay (ELISA), is then subsequently tested by an immunoblot analysis 
against B. burgdorferi lysate.  The latter method is a specific test, recommended in order 
to reduce the number of false-positives that are possible using only commercial enzyme 
assays (Ledue et al., 1996). 
 
Although ELISA using whole-cell lysates is the most frequently used format for 
the sensitive first-tier testing (Aguero-Rosenfeld et al., 2005), the outcome is inherently 
limited by difficulties in standardization.  The antigenic profile of in vitro-grown B. 
burgdorferi can significantly vary by growth phase, number of passages, composition of 
the complex culture media amongst other factors resulting in substantial batch-to-batch 
variation in ELISA kits (Schwan et al., 1988; Ramamoorthy and Philipp, 1998).  With 
millions of serum samples tested for LD each year, standardization and automation of 
serological testing are one of the major goals of LD research (Aguero-Rosenfeld et al., 
2005).  It has been suggested that dogs may serve as sentinels for LD, as they can be at a 




erythema migrans rash, laboratory diagnosis is important in cases of canine LD, further 
increasing the demand for serological testing (Appel et al., 1993).  Recombinant and 
synthetic antigen ELISA kits ease standardization, are amenable to automation, and may 
improve specificity by concentrating B. burgdorferi-specific epitopes. 
 
Many recombinant B. burgodorferi antigens and various fragments thereof have 
been evaluated as serodiagnostic markers for LD, including OspC (Padula et al., 1994), 
BmpA (Simpson et al., 1990), VlsE (Lawrenz et al., 1999), BBK32 (Heikkila et al., 
2002), L25 (Mueller et al., 2006), P37 (Magnarelli et al., 2000) and DbpA (Goettner et 
al., 2005).  OspC is exposed on the B. burgdorferi surface, is produced during early 
infection, and is highly immunogenic (Aguero-Rosenfeld et al., 1993; Dressler et al., 
1993; Padula et al., 1994; Engstrom et al., 1995).  A peptide fragment termed pepC10, 
containing a conserved immunogenic epitope, has been developed for serodiagnosis 
(Mathiesen et al., 1998).  Though immunogenic, significant protein sequence 
heterogeneity exists among B. burgdorferi isolates, constituting several serotypes, which 
limit the effectiveness of both OspC (Earnhart et al., 2005) and BmpA as serodiagnostic 
markers (Roessler et al., 1997).  VlsE is a dominant surface-exposed antigen of B. 
burgdorferi, a lipoprotein that undergoes antigenic variation by genetic recombination 
with silent vls cassettes (Zhang et al., 1997).  Expressed throughout late infection, VlsE 
and C6, a conserved peptide fragment of VlsE, have been evaluated as serodiagnostic 





These studies suggest that while the use of recombinant proteins can reduce cross-
reactivity, thereby enhancing specificity, the use of only select antigens can reduce the 
sensitivity of the diagnostic test (Magnarelli et al., 1996).  Some of the highest 
sensitivities reported thus far have used several antigens in combination to enhance 
diagnostic accuracy (Burbelo et al., ; Rasiah et al., 1994; Rauer et al., 1998; Kaiser and 
Rauer, 1999; Bacon et al., 2003).  However, there remains a need for improvement in 
sensitivity, especially for detection during the earliest stages of disease (Aguero-
Rosenfeld et al., 1993).  The addition of new immunogenic epitopes could allow these 
tests to eventually supplant the two-tiered approach, improving both the efficacy and cost 
of LD testing. 
 
In an effort to more completely catalogue antigens produced during infection, a 
recent study by Barbour et al. used synthetic protein arrays to test the immunogenicity of 
the majority of B. burgdorferi open reading frames (Barbour et al., 2008).  Though most 
open reading frames were not measurably immunogenic, they identified several novel 
antigens, including BBK07 and BBK12, putative lipoproteins from the linear plasmid 
lp36.  These proteins are extremely similar in sequence, though BBK07 is slightly larger 
than BBK12 (250 and 232 amino acids, respectively) (Fraser et al., 1997b).  The genes 
are members of paralogous family 59, and are 87% identical in their overlapping amino 
acid sequences.  While both BBK07 and BBK12 were identified as immunogens and 
potential antigenic markers, a detailed characterization of their expression and the 




surface localization and immune response against BBK07 to further evaluate its inclusion 
as diagnostic marker to improve the accuracy and sensitivity of LD serodiagnosis. 
 
I then tested the sensitivity and specificities of BBK07-based diagnosis using 
serum samples from North American and European patients with diagnosed LD and 
several other conditions including syphilis and autoimmune diseases.  I also assessed the 
serodiagnostic abilities of BBK07 using a full-length protein and an overlapping peptide 
library, identifying the most immunogenic epitopes of BBK07.  I demonstrate that serum 
testing using a combination of peptides was superior to full-length BBK07 protein.  
Finally, I show that the peptides are able to detect both canine and human LD effectively, 
even during the early stages of the disease. The IgG or IgM ELISA further show that a 
cohort of human LD sera failed to recognized VlsE-derived C6 or OspC-derived pepC10 
peptides but exclusively reacted with BBK07 peptides suggesting their potential for 





5.2 Materials and methods 
 
Bacteria, ticks and mice.  Isolate A3, a clonal derivative of Borrelia burgdorferi B31 
M1 and a generous gift from Dr. Patricia Rosa was used throughout the study.  Bacteria 
were grown in BSK-II media at 34°C.  The Ixodes scapularis ticks used in this study 
were maintained in the laboratory as described (Pal et al., 2004a).  C3H/HeN mice were 
purchased from the National Cancer Institute.  All animal procedures were performed in 
compliance with the guidelines and with the approval of the Institutional Animal Care 
and Use Committee.  For generation of immunized serum, each mouse was injected with 
100 μg of B. burgdorferi sonicate (5 mice/group) intradermally.  As injections with lysed 
spirochetes were performed without an adjuvant, all booster injections were performed at 
weekly intervals for 9 weeks.  Polyclonal antibodies against truncated BBK07 protein 
representing amino terminal region of the mature protein (BBK07N) were obtained by 
injecting mice intradermally with recombinant protein (10 μg/animal) emulsified in 
complete Freund’s adjuvant once, and twice in incomplete Freund’s adjuvant (Sigma) at 
10 day intervals.  Serum was collected and pooled 10 days after final injection (Coleman 
et al., 2008).  Infected mouse serum was obtained by needle inoculation with Isolate A3, 
297 (Pal et al., 2004b), or clinical isolates B408, B491, B500, B515, BL203, or BL206 
isolated from human patients as described (Wang et al., 2002). 
 
Purification of recombinant proteins.  The recombinant protein fragment BBK07N, 
containing amino terminal part of the protein and excluding the signal peptide, amino 




pET302/NT-His Champion vector (Invitrogen).  The following oligonucleotide primers 
were used to construct the expression vector: forward primer (5’ AAT CTA GAA TGT 
GGC ATG TAG ACA ATC CCA TTG 3’, XbaI site italicized), reverse primer (5’ CCG 
GGA TCC ATT ACA TCT TTA GTC CAT TCT T 3’, BamHI site italicized).  
Purification was performed using commercial cell lysis buffer (FastBreak, Promega) and 
MagneHis nickel particles (Promega) according to the manufacturer’s instructions.  
Recombinant VlsE was a generous gift from Fang Ting Liang from Louisiana State 
University.  Recombinant BmpA (Pal et al., 2008b), Lp6.6 (Lahdenne et al., 1997), OspC 
(Pal et al., 2004b) and BbCRASP-2 (Coleman et al., 2008) were purified as detailed.  
Full-length BBK07 protein was produced in insect cells using the Bac-to-Bac 
Baculovirus Expression System (Invitrogen).  The complete BBK07 open reading frame 
without the native signal peptide was amplified using the following primers, with 
restriction sites italicized: (forward primer with BamHI site, TTT CGG ATC CAT GCA 
CCA CCA CCA CCA CCA CTG GCA TGT AGA CAA TCC CAT TG; reverse primer 
with XhoI site, CCC CCT CGA GAA TTA ATT ATT AAA GCA CAA ATG T).  The 
resulting amplicon was inserted into the pFASTBAC-1 vector.  A recombinant bacmid 
was generated with the amino terminal histidine-tagged BBK07 driven by the polyhedrin 
promoter.  Transfection and protein expression were performed in Sf9 cells, according to 
the manufacturer’s instructions.  The protein was purified using nickel resins (Probond 
system, Invitrogen) to 95% purity, as assessed by SDS-PAGE analysis. 
  
Gene expression analysis.  Infected ticks (3 ticks per time point), as well as infected 




mortar and pestle under liquid nitrogen, and total RNA extracted using TRIzol reagent 
(Invitrogen).  RNA from log-phase in vitro-grown B. burgdorferi (107 spirochetes/ml) 
was also isolated using TRIzol reagent (Invitrogen).  The purified RNA was treated with 
DNase I (NEB) to reduce DNA contamination.  One microgram of total RNA from each 
sample was used to synthesize cDNA using AffinityScript first-strand cDNA synthesis 
(Stratagene).  Quantitative RT-PCR (qRT-PCR) analysis was performed on 50 μg of each 
cDNA using iQ SybrGreen Supermix (BioRad).  To help protect against DNA 
contamination, cDNA was compared to an equal concentration of template RNA to 
measure the contribution of DNA to the final results.  Standard curves for flaB and bbk07 
were generated using B. burgdorferi genomic DNA purified by DNeasy Blood and 
Tissue Kit (Qiagen).  The following primers were used for qPCR: flaB (5’ TTC AAT 
CAG GTA ACG GCA CA, GAC GCT TGA GAC CCT GAA AG 3’), bbk07 (5’ CCT 
ATT TCA AGG GCG TGA GC, TAT GGC CAT TGC TGC ATT CT 3’), bbk12 (5’ 
GCT GAA AAT TCG GTA AGC GTT T, TAA GTT CGC TGC ATA CAC CTT CA 
3’). 
 
Proteinase K accessibility assay.  Proteinase K accessibility assays were performed as 
described (Brooks et al., 2006), with the following modifications.  B. burgdorferi (1×109) 
were gently washed three times in 1 ml of PBS (pH 7.4) and collected by centrifugation 
at 4,000×g for 5 min.  Washed spirochetes were then gently resuspended in 100 μl of 
PBS and split into two equal 50 μl volumes.  One aliquot received 10 μg of proteinase K 
(PK) (Sigma) in PBS while the other aliquot received an equal volume of PBS without 




3 times with 1 ml PBS with 1 mM phenylmethylsulfonylfluoride (Sigma) to stop PK 
activity.  After washing, the spirochetes were resuspended in PBS and used for 
immunoblot analysis.  Polyclonal BBK07N antisera was used for immunoblot at a 1:2000 
dilution in 5% skim milk.  FlaB and OspA antisera was used as described (Yang et al., 
2009). 
 
Serum.  Serum samples used in the line blot assay were provided by Genzyme Virotech 
(Germany).  For ELISA, the healthy control sera included 25 samples from normal 
individuals that tested negative for LD, which were provided by CDC and Marylou 
Breitentein at Yale University.  These control sera were used to define the cutoff value in 
each assay (mean plus 3 SD).  Additional infected serum panels were provided by the 
CDC.  Serum panel 1 consisted of 33 serum samples collected from human patients 
diagnosed with LD, between 2 weeks and 13 years after the onset of symptoms.  Serum 
panel 2 consisted of 60 samples collected from 20 culture-positive patients that presented 
to medical doctors with erythema migrans.  Serum was collected at the first doctor visit 
after the onset of disease (day 0), and at subsequent visits, 10 and 20 days thereafter.  
Canine serum samples were provided by the Synbiotics Corporation, and consisted of 




ELISA and immunoblotting.  For ELISA, antigens were diluted in 50 mM carbonate-




Recombinant proteins and B. burgdorferi lysate were coated using 100 ng per well, and 
all synthetic peptides using 500 ng per well.  BBK07 peptides and the C6 peptide were 
coated directly on ELISA plates.  Although the BBK07 peptides were biotinylated at the 
N-terminus, experiments using streptavidin-coated plates did not influence the sensitivity 
of the assay (data not shown).  However, in experiments using the pepC10 peptide, the 
plates were first coated with 400 ng per well of streptavidin (MP Biomedicals) before the 
addition of the peptide, in order to enhance sensitivity.  The mean OD values of the 
control sera plus 3 SD was considered the cutoff value to determine positivity in each 
sample.  The plates were blocked using 1% bovine serum albumin in PBS-T (phosphate 
buffered saline with 0.05% Tween-20), and plates were washed extensively between all 
steps with PBS-T.  Human and canine sera were diluted in 1:200 or 1:10, respectively, in 
1% BSA in PBS-T.  Immunoblots were performed using nitrocellulose membranes 
blocked with 5% skim milk in PBS-T, using murine serum dilutions from 1:200 to 
1:2000.  Secondary antibodies against IgG conjugated to horseradish peroxidase were 
used with the following dilutions: goat anti-mouse IgG 1:10000, goat anti-human IgG 
1:5000, goat anti-human IgM 1:20000, and goat anti-dog 1:2000 (KPL). All steps were 
carried out either for one hour at 25°C or overnight at 4°C.  ELISA results were 
quantified using SureBlue TMB Substrate and TMB Stop Solution (KPL).   
  
For line blot assay, recombinant protein was transferred to nitrocellulose 
membranes by a microdispensing method as described (Goettner et al., 2005).  Strips 
were incubated with human sera (dilution 1:100) and the binding of specific antibodies 




(1:100; Genzyme Virotech, Germany). Immunoreactive bands were visualized with the 
addition of tetramethylbenzidine substrate.  Cutoffs were based on a standardized band 
intensity scale (Genzyme Virotech GmbH, version VI 0803093) of 0 to 5, with 5 as the 
most intense and 0 as no band visible. Line blots were considered positive if the band 
intensity was >2. 
 
Peptide synthesis.  A total of 23 overlapping peptides (P1-P23) encompassing the 
mature BBK07 protein were commercially synthesized (PEPscreen system, Sigma).  The 
peptides were 14 amino acids in length, with an overlap of 4 amino acids on the amino 
and carboxyl terminal sides.  The C6 peptide 
(CMKKDDQIAAAMVLRGMAKDGQFALK) (Liang et al., 1999) and pepC10 peptide 
(PVVAESPKKP) (Mathiesen et al., 1998) were also commercially synthesized 
(FlexPeptide system,GenScript USA).  All peptides were labeled with biotin at the 
amino-terminus, and were dissolved in dimethyl sulfoxide, aliquoted and stored at -20°C 
until use. 
 
Statistics.  Results are expressed as the mean ± standard error of the mean (SEM).  The 
significance of the difference between the mean values of the groups was evaluated by 
two-tailed Student t-test.  MedCalc (MedCalc Software, Mariakerke, Belgium) was used 
in the comparison of diagnostic tests.  Diagnostic performance of each antigen was 
compared pairwise using area under curve (AUC) from receiver operator characteristic 








bbk07, but not the  paralogous gene bbk12, is selectively expressed in the mammal 
during the  infection cycle of B. burgdorferi.  The paralogous gene products bbk07 and 
bbk12 have recently been identified as potential immunogens of B. burgdorferi (Barbour 
et al., 2008).  The genes are highly homologous, with 87% amino acid identity in their 
overlapping sequences (Fraser et al., 1997b).  Due to the nearly identical sequences of 
BBK07 and BBK12, it is unclear if the host immune response is directed against either or 
both genes.  To ascertain their individual expression patterns, I developed two sets of 
oligonucleotide primer pairs targeting variable regions of each gene, which specifically 
amplified either bbk07 or bbk12 with low cross-reactivity, as confirmed by the DNA 
sequencing of the corresponding amplicons.  These primers were then used to determine 
the relative expression levels of each gene in cultured spirochetes or infected host tissue 
by qRT-PCR analysis.  While both genes were transcribed at relatively low levels in 
vitro, only bbk07 was detectable in vivo, as shown in infected mouse dermis 1 week after 
inoculation (Fig. 12).  Strikingly, the transcriptional level of bbk07 is more than 100 fold 
higher in the infected host tissue than in vitro. 
 
Because of the relatively high transcription level of bbk07 in the infected host 
tissue, I then studied the expression of bbk07 in the B. burgdorferi life cycle, covering the 




tick and mouse tissues to generate cDNA representative of important stages in the B. 
burgdorferi life cycle: transmission from infected ticks, murine infection, acquisition by 
naïve ticks, and persistence through the tick molt.  While consistently expressed in 
multiple murine tissues during the first 4 weeks of murine infection, the transcription of 
bbk07 was dramatically reduced below the limit of detection in all tested stages of ticks 
(Fig. 13).  The same RNA samples did not contain detectable quantities of bbk12 
transcripts at any tissues or time point examined. 
 



























Figure 12.  bbk07 is selectively expressed during infection.  
bbk07 and bbk12 expression by B. burgdorferi.  qRT-PCR was performed using 
gene-specific primers to determine if bbk07, bbk12, or both are transcribed by B. 
burgdorferi in vivo and in vitro, normalized to flaB.  Both gene transcripts were 
detectable at relatively low levels in vitro, but only bbk07 transcripts were present 






Amino-terminal region of BBK07 is surface exposed and immunogenic.  Since bbk07 
is annotated as a lipoprotein, which might be exposed on the spirochete surface, I next 
assessed the surface localization of BBK07.  Expressing a full-length or truncated protein 
representing carboxy-terminal half of BBK07 proved difficult in Escherichia coli, 
however, an amino-terminal fragment could be purified in sufficient quantities and used 
for further experimentation.  This fragment contained the amino terminus through the 
first half of the mature protein, referred to as BBK07N (Fig. 14A).  Specific antiserum 
was generated by immunizing mice with BBK07N and adjuvant. In agreement with a 
previous study showing the immunogenicity of in vitro translated BBK07 (Barbour et al., 
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Figure 13.  bbk07 expression pattern in vivo. 
The transcriptional profile of bbk07 throughout representative stages of the 
life cycle of B. burgdorferi was measured by qRT-PCR.  Mice (3 mice per 
time point) and ticks (3 ticks per time point) were infected with B. 
burgdorferi.  Total RNA was isolated from infected tissues representing the 
complete life cycle of B. burgdorferi: fed nymphs, infected murine tissues 
collected at weekly intervals through four weeks after infection, feeding 
larva, and unfed nymphs.  bbk07 was expressed in all murine tissues tested 
but was undetectable in tick samples.  Bars represent the mean and SEM 









To test the surface exposure of BBK07, a proteinase K accessibility assay was 
performed (Coleman et al., 2008).  Intact B. burgdorferi were incubated with and without 






























































Figure 14.  Amino terminal region of BBK07 is immunogenic. 
(A) Schematic of BBK07, showing location of recombinant amino-terminal BBK07 
protein fragment used in the current study.  A protein fragment lacking the putative 
signal peptide (grey box) starting from amino-terminal to half of the protein length 
was purified, and termed BBK07N. 
(B) Generated mouse anti-BBK07N sera recognizes recombinant truncated protein 
and native BBK07 (left panels), while recombinant BBK07N detects BBK07-specific 
antibody in infected mouse serum two weeks after infection (right panels).  Mice 
were immunized with BBK07N in order to generate BBK07N antiserum.  The 
resulting serum was used to probe 100 ng of purified BBK07N and 1 μg of B. 




subsurface protein, was not degraded, but both the surface protein OspA and BBK07 
were significantly degraded, suggesting that the amino terminal region of BBK07 is 
surface exposed (Fig. 15). 
 
BBK07-specific immune response is pronounced during active borrelial infection 
but absent in hosts immunized with lysed pathogens.  Because qRT-PCR analysis 
indicated a dramatic induction of bbk07 in vivo during early infection, I next assessed 
kinetics of BBK07 antibody development in the host over the first nine weeks of B. 
burgdorferi infection.  As qRT-PCR analysis indicated minor expression of bbk07 in 
vitro, I also assessed, in parallel, BBK07 antibody development in mice immunized with 
sonicated spirochetes, in order to test whether BBK07 could differentiate infected hosts 
from ones vaccinated with killed pathogens.  To accomplish this, groups of mice (5 
animals/group) were needle-inoculated with a single B. burgdorferi inoculum (105 







Figure 15. Surface exposure of BBK07. 
Viable B. burgdorferi cells were incubated 
with (+) or without (-) Proteinase K and 
subjected to immunoblotting using antiserum 
against BBK07N, FlaB and OspA.  FlaB and 
OspA were used as subsurface and surface 
controls, respectively.  While the levels of 
FlaB did not decrease, both OspA and 
BBK07 showed degradation in the presence 




sonicated B. burgdorferi (100 µg/mice) at 7 days intervals for a total of 9 weeks.  Serum 
samples were collected and pooled weekly.  Equal amounts of B. burgdorferi lysate or 
BBK07N were used to detect specific antibodies present in each serum sample by ELISA 
(Fig. 16A).  As a negative control, antibody development against the B. burgdorferi 
antigen Lp6.6, which is abundant in vitro but known to be downregulated during murine 
infection, was also measured (Lahdenne et al., 1997).  As expected, antibodies against B. 
burgdorferi lysate, but not against Lp6.6, were detected in infected mice (Lahdenne et al., 
1997; Brooks et al., 2003).  BBK07 provoked a robust antibody development that was 
detectable after one week, and remained elevated throughout the infection.  In contrast, 
the mice immunized weekly with lysed spirochetes produced a low BBK07 antibody 
response that did not increase over the course of the experiment, while Lp6.6 provoked a 
robust antibody response (Fig. 16B).  In order to confirm that the immunogenicity of 
BBK07 is not confined to needle-borne artificial murine infection, groups of naïve mice 
were infected by tick bite.  Serum samples were collected after 4 weeks of infection, and 
tested by ELISA (Fig. 16C).  The serum contained a similar response against both lysate 
and BBK07, indicating that the antibody response against BBK07 does not depend on 







Evaluation of BBK07N as a diagnostic marker for B. burgdorferi infection in murine 
hosts.  The robust and specific immune response provoked by BBK07 led me to 
investigate a possible diagnostic use of BBK07N.  Using mouse serum collected 2 weeks 
after infection, I compared the immunogenicity of BBK07N to several other 
immunogenic B. burgdorferi antigens, such as VlsE, OspC, BmpA and BbCRASP-2.  As 
Infected with B. burgdorferiA
Immunized with lysed B. burgdorferiB
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Figure 16.  BBK07-specific antibody develops early during infection but absent in 
hosts immunized with lysed pathogens. 
(A) BBK07 antibodies are detectable during early infection.  Serum samples from mice 
needle-inoculated with B. burgdorferi were collected at several time points after infection.  
The immune response to B. burgdorferi lysate, purified Lp6.6 and BBK07N proteins was 
measured by ELISA.   
(B) Mice immunized with sonicated B. burgdorferi generate an insignificant immune 
response against BBK07.  Mice were immunized weekly with B. burgdorferi lysate and 
serum samples were tested by ELISA.   
(C) BBK07 antibodies present during natural tick-borne infection of mice.  Mice were 
infected by tick bite, and serum samples tested by ELISA.  The immune response was 





controls, B. burgdorferi lysate and Lp6.6 were also included in the assay.  To measure the 
relative immunogenicity of each antigen, equal amounts of proteins and lysate were used 
in an ELISA, probed with the infected mouse serum (Fig. 17).  Due to the high antibody 
titers detected by BBK07N and VlsE, which quickly reached upper detection limit of the 
assay, the reaction was stopped shortly (1 minute) after the addition of chromogenic 
substrate.  As expected, naïve sera had low reactivity to all antigens.  Amongst all 
antigens tested, BBK07N reflected the most robust immune response, proving more 
sensitive than several antigens currently used in LD diagnosis. 
 
 
















Figure 17.  Comparative immunogenicity of BBK07 against other antigens in mice. 
Pooled sera from groups of two-week post-infection (black bars) and uninfected (white 
bars) mice were used to probe 100 ng of purified proteins or sonicated B. burgdorferi 
lysate and the levels of specific antibody responses were measured by ELISA.  Naïve 
mouse sera had low reactivity to all antigens.  As wells containing BBK07N and VlsE 
quickly reached the upper detection limit of the assay, the reaction was stopped 1 minute 
after the addition of the chromogenic substrate.  The bars represent the mean and SEM 
from duplicate measurements of two independent mouse experiments.  Except for VlsE, 
differences in antibody responses against BBK07N are significantly higher than other 




BBK07 is highly sensitive and specific against B. burgdorferi infection in North 
American and European patients.  As BBK07N protein proved highly reactive in 
infected murine sera, I next evaluated if it could be used for detection of human LD in 
North America.  While bbk07 is highly conserved among B. burgdorferi sensu stricto 
isolates present both in North America and Europe, there are additional borrelial 
genospecies that cause LD, also known as Lyme borreliosis (LB) in Europe, such as B. 
garinii and B. afzelii.  The latter species do not contain linear plasmid 36 (plasmid k) that 
harbors the bbk07 gene, and lack an orthologue of BBK07.  Therefore, while BBK07 
serodiagnosis could be ineffective in Europe for universal diagnosis of LB, but it could 
be useful in discriminating B. burgdorferi infection from other genospecies.  To test this 
hypothesis, the recombinant BBK07N was tested using a line blot assay which is widely 
used for serodiagnosis of LB in Europe (Hunfeld and Kraiczy, 2009). To assess the 
specificity of BBK07-based diagnosis, a set of 20 German and United States patients with 
diagnosed infection, as well as serum from normal healthy individuals, pregnant women, 
and patients with other conditions, including autoimmune diseases, and syphilis were 
compared in a line blot assay and the results were scored using a standardized band 
intensity scale (Table 4).  While BBK07 was highly sensitive (90%) in detecting B. 
burgdorferi infection in serum from the United States, the German patients with LB, 
other diseases, or healthy controls showed minor reactivity.  These data underscore the 
high sensitivity and specificity of BBK07-based diagnosis of B. burgdorferi infection in 
US patients.  The observed lower sensitivity of BBK07 reactivity in European LB patient 









BBK07N line blot results 
US sera Lyme IgG positive 18/20 90% 
Early Lyme Disease 1/20 5% 
Neuroborreliosis 1/20 5% 
Lyme arthritis 2/20 10% 
German sera 
ACA 4/20 20% 
Healthy blood donors 0/20 0% 
EBV infections 0/10 0% 
Syphilis infections 0/10 0% 
Pregnant women 0/10 0% 
Autoimmune diseases 1/10 10% 
Control sera 
Rheumatoid factor 0/10 0% 
Human serum samples were analyzed by a line blot assay containing various amounts 
of the recombinant fragment BBK07N.  ACA, Acrodermatitis chronica atrophicans; EBV, 




BBK07-specific immune response is elicited during murine infection with several 
clinical isolates of B. burgdorferi sensu stricto.  In order to further characterize the 
diagnostic potential of BBK07, I measured its conservation and immunogenicity in 
multiple clinical strains, which were isolated from human patients from North America 
(Wang et al., 2002).  The B. burgdorferi clinical isolates were grown in BSK medium, 
were injected into mice, and serum was collected at 2 or 3 weeks following infection.  
Infected sera were used to probe recombinant BBK07N protein by immunoblot analysis 
(Fig. 18).  A BBK07-specific antibody response was highly detectable in mice infected 
with the B. Burgdorferi B31 laboratory isolate A3, as well as all clinical isolates.  These 
data highlight the ability of BBK07-based serodiagnostic assay to detect LD infection 





Identification of immunogenic epitopes of BBK07.  I next mapped the 
immunodominant epitopes of BBK07 using human sera.  To accomplish this, a library 
consisting of 23 overlapping peptides was synthesized, covering the full-length mature 
BBK07 (Table 5).  Each peptide was tested for ELISA reactivity in serum samples from 
25 healthy donors, and 33 patients diagnosed with LD from serum panel 1.  Given the 
number of peptides and the limited supply of serum, all peptides were screened once with 
each serum sample, and the most immunogenic peptides were repeated in three 
independent experiments to validate the results.  Results indicated that peptides P1 
(CKWHVDNPIDEATA), P5 (ITKLTPEELENLAK), and P7 (EKSKKEIEDQKNTK) 
harbored the most immunodominant epitopes recognized by the infected sera (Fig. 19A).  
Samples were considered positive if they exceeded the cutoff value in at least 2 out of 3 
independent ELISA (Fig. 19B).  I speculated that additional testing of other peptides was 
unlikely to significantly increase sensitivity, as the serum samples reactive to other 




















B. burgdorferi isolate-specific infected sera
BBK07N
Immunoblot  
Figure 18.  Conservation of BBK07 immunoreactivity in 
clinical B. burgdorferi isolates. 
Mice were infected with several B. burgdorferi isolates 
isolated from infected human patients in North America.  
Serum from the infected mice was collected and used to 
probe 200 ng of recombinant BBK07N protein to test for an 
immune response against BBK07.  A BBK07-specific 
immune response was detected in the widely-used 
laboratory strain (A3), as well as each mouse infected with 
a human isolate (297 through BL206).  No antibodies were 




these 3 peptides and repeated measurements confirmed that amongst the P1, P5 and P7 
peptides, P5 housed the most immunogenic epitopes and was able to distinguish 24% (8 
out of 33) of the LD diagnosed patient sera from control.  In order to assess if the 
combination of the three most immunogenic peptides increased the sensitivity of the 
assay, the peptides were mixed and tested against the serum panel (Fig. 19B).  The results 
indicated that the combination of 3 peptides had a synergistic effect and increased the 
diagnostic accuracy to 52% (P1P5P7, 17 out of 33), significantly increasing the test 
performance by receiver operator characteristic (ROC) analysis (P<0.05). 
 
 

































A peptide combination of BBK07 provides greater diagnostic accuracy than 
recombinant BBK07.  I have demonstrated that a combination of BBK07 peptides and a 
recombinant amino-terminal fragment of BBK07 (Coleman and Pal, 2009) are effective 
in LD diagnosis.  To see if the presence of conformational epitopes could improve the 
sensitivity of BBK07-based serodiagnosis, I produced recombinant full-length BBK07 in 
insect cells using a baculovirus expression system.  The full-length protein was tested 
against serum panel 1 as detained before, and its reactivity was compared to the 
recombinant amino-terminal fragment BBK07N, and the BBK07 peptide combination.  
B. burgdorferi lysate was also included as a positive control. Three independent 

























Figure 19.  Identification of immunodominant epitopes of BBK07. 
(A) Epitope mapping of BBK07 using infected human sera.  A library of 23 overlapping 
BBK07 peptides was screened for reactivity in sera from 33 patients diagnosed with Lyme 
disease (LD) or from 25 healthy donors.  Microtiter wells were coated with individual 
BBK07 peptides (500 ng/well) and incubated with individual patient or healthy donor 
serum (1:200 dilutions).  The signal was generated using goat secondary antibodies 
against human IgG conjugated to horseradish peroxidase at the dilution of 1:5000.  The 
cutoff value for each peptide was the mean plus 3 SD of the healthy control sera.  Bars 
represent the percentage of diagnosed serum samples above the cutoff value. 
(B) A peptide combination significantly enhances BBK07-based serodiagnostic ability 
compared to individual peptides.  Peptides P1, P5, P7, and all 3 peptides combined 
(P1P5P7) were tested in three independent ELISA measurements for reactivity with 
human serum.  Serum samples were considered positive if above the cutoff value in at 




representative experiment is shown (Fig. 20).  While I expected that the full-length 
BBK07 (13 out of 33, 39%) should provide more epitopes for antibody recognition, the 
amino-terminal fragment BBK07N (14 out of 33, 42%) shows no significant reduction in 
diagnostic accuracy, as assessed by statistical analysis (P=0.181).  However, the peptide 
combination (17 out of 33, 52%) showed a superior diagnostic accuracy than either 
BBK07N or full-length BBK07.  Statistical analyses further indicated that there was a 
significant improvement in test performance from the full-length protein to the peptide 
combination (P=0.048), but not between the peptide combination and the recombinant 
fragment BBK07N (P=0.252).  
 
BBK07 peptide-based diagnosis is effective during early infection.  I next assessed if 
BBK07-based diagnosis is effective in early LD infection.  Since the peptide combination 







Figure 20.  Immunoreactivities of full-length or truncated BBK07 proteins and 
peptides to individual Lyme disease patient sera. 
Microtiter wells were coated with 100 ng of B. burgdorferi lysate (Bb lysate), recombinant  
full-length BBK07 protein (BBK07), the N-terminal BBK07 fragment (BBK07N), or a 
combination of immunodominant peptides P1, P5, and P7 (P1P5P7, 500 ng each).   
Immunoreactivity of individual serum samples from healthy donors (black circle) and from 
patients diagnosed with LD (white circle) was measured by ELISA. The horizontal dashed 
line indicates the cutoff value calculated for each antigen from the healthy sera.  Values 




displayed the highest BBK07-based serodiagnostic efficiency, this was used in the study.  
Serum samples (serum panel 2) were collected from patients displaying erythema 
migrans on their first visit to a physician.  Biopsies from all patients were later culture 
positive for B. burgdorferi, and serum from each patient was collected again at 10 and 20 
days after the first visit (day 0) to the doctor.  Note that the serum is first collected from 
the patients upon their first visit to a physician, and not the time of initial exposure.  
Therefore, while it is not known how long after infection the serum samples were 
collected, the appearance of erythema migrans on their first visit to a physician makes it 
likely to be within the first few weeks of B. burgdorferi infection (Steere, 2006). The 
control sera from serum panel 1 were used to define the cutoff for each antigen as 
detailed before, and each antigen was used to test serum panel 2 in three independent 
measurements.  The BBK07 peptide combination P1P5P7 had a similar diagnostic 
accuracy detecting IgG at day 10 as observed using serum panel 1 (10 out of 20, 50%) 
(Fig. 21).  To further assess the effectiveness of the P1P5P7 peptide combination in the 
diagnosis of early disease, it was tested for both IgM and IgG reactivity using appropriate 
controls, such as the OspC peptide pepC10 for IgM (Mathiesen et al., 1998) and the VlsE 
peptide C6 for IgG detection (Liang et al., 1999). The results show that, compared to 
BBK07, the peptides pepC10 and C6 showed higher overall sensitivities in detecting IgM 
and IgG, respectively (Table 6).  However, a subset of patients that displayed negative 
reactivity to the pepC10 and C6 peptides positively reacted against P1P5P7 combination 
(Table 6).  These data indicate a heterogeneity in the immune response of the tested 
patients, and suggests the potential use of BBK07 peptides for enhancing the diagnostic 













Figure 21.  BBK07 antibody development in LD patients during early infection. 
Early immunoreactivity to BBK07 peptides.  The BBK07 peptide combination 
(P1P5P7) was assessed for immunoreactivity against the same cohort of human 
patients during early LD.  Sera from a group of twenty patients experiencing the 
early symptoms of LD were collected during the initial doctor visit (Day 0) and two 
subsequent visits (Day 10) and (Day 20) and were used in the assay.  Sera from 
twenty normal healthy controls were used to establish a cutoff value, and a 




Table 6.  Individual patient reactivity against BBK07 (P1P5P7), OspC (pepC10) 
and VlsE (C6) peptide-based serodiagnosis of early LD 
 
IgM P1P5P7 pepC10 
Patient Initial visit Day 10 Day 20 Initial visit Day 10 Day 20 
1 - + + - - - 
2 - - - - + + 
3 - - - - + + 
4 - - - - - - 
5 - - - - - - 
6 - - - - - - 
7 - - - - - - 
8 - - - - + + 
9 - - - - - - 
10 - - - + + + 
11 - - - - - - 
12 - - - + + + 
13 - + - - + + 
14 - + - - + + 
15 - - - + + + 
16 - + - - + - 
17 - - - - - - 
18 - - + - - - 
19 - - - - - - 
20 - - - - + + 
 
IgG P1P5P7 C6 
Patient Initial visit Day 10 Day 20 Initial visit Day 10 Day 20 
1 - + + + + + 
2 - + - + + + 
3 - - - - - - 
4 - - - - - - 
5 - - - - + + 
6 - - - + + + 
7 - - - + - - 
8 - - - - + + 
9 + + + - - + 
10 - - - + + + 
11 - + - + + + 
12 - - - + + + 
13 - + + - + + 
14 - + + - - - 
15 - + + + + + 
16 - + + - + + 
17 + + + + + + 
18 - + + - - - 
19 - - - + + + 




BBK07 peptide-based diagnosis is highly effective in canine LD.  As BBK07 
immunoreactivity is an effective serodiagnostic marker for the detection of B. burgdorferi 
infection in mice and humans (Coleman and Pal, 2009), I next assessed if the antigen 
could be used to detect LD in dogs that are routinely screened for LD infection.  A panel 
of 55 uninfected and 46 B. burgdorferi-infected canine serum samples was assessed using 
the BBK07 peptides P1P5P7 in an ELISA as before.  The assay was repeated with similar 
results, and a representative experiment is shown (Fig. 22).  The results show that, like 
humans, a peptide from BBK07 is also effective (35 out of 46, 76%) for the detection of 












Figure 22.  Immunodominant BBK07 peptides as a potential 
antigenic target for serodiagnosis of canine Lyme disease.   
Canine sera from healthy individuals (black circles, n=55) and ones 
diagnosed with Lyme disease (open circles, n=46) were used to assess 
immunoreactivity of the BBK07 peptide combination P1P5P7 by ELISA. 
Optical density values of control dog serum were used as controls to set 







The identification and characterization of in vivo antigens of B. burgdorferi is 
central to the improvement of current laboratory diagnostics for LD.  A previous study 
identified BBK07 and BBK12 as novel immunogenic antigens of B. burgdorferi (Barbour 
et al., 2008).  I further extend the observation and establish that bbk07, but not highly 
similar paralogous member bbk12, was expressed at relatively high levels in vivo.  I show 
that a recombinant protein representing the amino-terminal region of BBK07 was able to 
provoke a specific antibody response against the native protein, providing antibodies that 
were then used to demonstrate the surface exposure of the amino-terminal region of 
BBK07.  The recombinant protein could, accordingly, detect a specific antibody response 
to active infection with B. burgdorferi.  As bbk07 had negligible expression in vitro, I 
show that this antigen could be useful in discriminating antibody development during 
active infection versus hosts vaccinated with killed pathogen preparations.  The detected 
antibody response during murine infection was more robust than that detected by several 
previously characterized serodiagnostic antigens (Bacon et al., 2003; Aguero-Rosenfeld 
et al., 2005). 
  
 To further evaluate the potential of BBK07 as a serodiagnostic marker, I assessed 
its sensitivity and specificity using diverse sets of serum collected from the United States 
and Germany where patients were chosen from diagnosed LD, several relevant and cross-




different clinical isolates of B. burgdorferi originally cultured from human patients, each 
isolate prompted a robust antibody response to BBK07, suggesting wide conservation of 
BBK07 immunogenicity amongst clinical isolates.  Using a library of 23 overlapping 
peptides and a human LD serum panel, I have identified most immunodominant epitopes 
of BBK07.  I also compared the reactivity of BBK07 peptides and proteins and show that 
the combination of three amino terminal peptides is a significantly more effective 
serodiagnostic marker than the full-length antigen.  I then show that this peptide 
combination can be used as a marker in the earliest stages of disease, effectively 
diagnosing some patients that lack reactivity to the OspC peptide (pepC10) or VlsE-
derived C6 peptide.  Finally, I show that these results may be applicable to other non-
human species at high risk of B. burgdorferi infection, as a peptide from BBK07 was able 
to effectively detect LD in canine serum samples.  Overall, these data identified most 
immunodominant epitopes of BBK07 and highlighted the usefulness of a peptide 
combination of BBK07 as potential components of a highly sensitive and specific test for 
human and canine LD. 
 
These data completely support a previous study showing that BBK07 is highly 
immunogenic during LD (Barbour et al., 2008).  However, plasmid lp36, which 
contained bbk07 locus could be lost during in vitro growth (Jewett et al., 2007), and these 
data showing extremely low in vitro expression of bbk07 suggest that BBK07 is under-
represented in tests using in vitro grown B. burgdorferi (Barbour et al., 2008).  The 
inclusion of BBK07 as a diagnostic marker could increase serodiagnostic sensitivity in 




tests.  The low in vitro expression of bbk07 and undetectable immune response against 
sonicated borrelial cells suggests additional use of BBK07 in animal LD diagnosis.  An 
animal LD vaccine is commercially available that utilizes killed in vitro grown B. 
burgdorferi (Chu et al., 1992; LaFleur et al., 2009).  The presence of BBK07 antibodies 
could serve as an indicator of active infection, as BBK07 reactivity is unlikely in 
vaccinated animals immunized with cultured organisms (Gauthier and Mansfield, 1999).  
Thus, BBK07 could differentiate between infected and vaccinated animals.  Sequence 
analysis also indicates that Borrelia garinii and Borrelia afzelii, the most prevalent 
causative agents of LD in Europe and Asia, lack an ortholog to BBK07 therefore, BBK07 
reactivity could be used to discriminate human LD caused by B. burgdorferi from that 
caused by other strains.  As expected, these data show that patients from North America 
had a higher reactivity than European patients. 
 
The effectiveness of some B. burgdorferi antigens has been reduced by sequence 
variation in the bacterial population, including VlsE (Iyer et al., 2000), OspC (Earnhart et 
al., 2005), and BmpA (Roessler et al., 1997).  These data indicate that BBK07 
immunoreactivity is detectable across the B. burgdorferi isolates present in North 
America, but not in European LD patients. Although the bbk07 gene is highly conserved 
in B. burgdorferi sensu stricto isolates in United States, the linear plasmid carrying the 
bbk07 gene or an ortholog thereof is absent in major B. burgdorferi sensu lato strains 
prevalent in Europe.  Therefore, while BBK07 diagnosis is unlikely to be effective in 
Europe, reactivity to BBK07 or similar antigens absent in other B. burgdorferi sensu lato 




with B. burgdorferi or the European strains (Barbour et al., 2008).  As immunoreactivity 
could potentially vary across mammalian species, the effectiveness of a BBK07 peptide 
to diagnose canine LD also testifies to the future use of BBK07-based diagnosis in 
companion animals.   
 
These data show that BBK07 peptides could be used to correctly diagnose nearly 
50% of the tested human sera.  While this is well below the sensitivity required of a 
stand-alone test, it suggests that BBK07 peptides could be a valuable addition to a future 
multi-antigen test.  Though many other B. burgdorferi antigens have been studied for 
their diagnostic potential (Aguero-Rosenfeld et al., 2005), no single antigen has proved 
sensitive enough to replace the current two-tiered testing recommended by the CDC, 
especially in the early stages of LD.  Therefore, several studies have evaluated antigen 
combinations intended to increase the test sensitivity (Aguero-Rosenfeld et al., 2005).  
Peptide antigens are highly desirable in this application, as a reduced antigen size can 
minimize the chances of cross-reactivity and maximize the concentration of important 
epitopes.  Additionally, compared to bacterial antigens used in serodiagnosis, the use of 
synthetic peptides has the advantage of less cross-reactivity to uninfected humans 
exposed to microbial infection.  These data show that a combination of several BBK07 
peptides is more effective than the full-length recombinant BBK07 in LD diagnosis, and 
thus is an attractive candidate for future peptide diagnostics. 
 
My primary screen of the peptide library showed that the most immunogenic 




agreement with my data showing that an amino-terminal recombinant fragment of 
BBK07, BBK07N, had a similar diagnostic accuracy to that of the full-length protein.  
My previous work also indicated that the amino-terminal half of BBK07 was accessible 
to protease degradation on the surface of B. burgdorferi cells.  Taken together, these data 
confirm that the amino-terminal region is highly antigenic, and thus is a prime target for 
the host’s immunological response, thus housing the most immunodominant epitopes of 
BBK07.  Two of the most effective BBK07 peptide antigens, P5 and P7, are situated only 
six amino acids apart on the amino-terminal region of BBK07.  Their proximity 
immediately suggests that a longer peptide, encompassing P5, P6, and P7, could 
effectively harness the linear epitopes of each on a single molecule.  In addition, the 
longer peptide could form limited conformational epitopes present in this region of the 
protein, further increasing sensitivity. 
  
BBK07 peptide diagnosis could be enhanced by improvements in antibody 
detection techniques.  In this study, I utilized a simple ELISA test, absorbing the peptides 
directly on the plastic surface in a high pH buffer.  The sensitivity of the test is then 
dependent on the ability of the plate to bind and present the peptide.  In this assay, each 
peptide was biotinylated on their amino-terminus, but streptavidin-coated plates did not 
increase the sensitivity of the test.  Chemical conjugation to solid surfaces or fusions with 
carrier proteins have been used in the past to improve peptide binding and display, and 
could be applied to further enhance sensitivity of BBK07 peptide-based diagnosis 
(Gomara and Haro, 2007).  A recent study demonstrated enhanced sensitivity of LD 




technique is performed entirely in the liquid phase, and has a broad dynamic detection 
range.  Their highest sensitivity was achieved using a synthetic peptide hybrid containing 
epitopes from the B. burgdorferi proteins OspC and VlsE.  These data show that BBK07 
peptides were able to detect an antibody response in several patients that did not react 
with the VlsE peptide C6 or the OspC peptide pepC10.  Therefore, it is likely that the 
inclusion of BBK07 peptides could enhance the sensitivity of other tests containing these 
antigens.  In conclusion, these data show that despite their small size, peptides from 
BBK07 are more effective than the full-length BBK07 protein, have the ability to detect 
both late and early human infections, and can detect a variety of B. burgdorferi infectious 
isolates.  These factors, combined with their unique ability to detect B. burgdorferi in 
patients not reactive to C6 or pepC10 peptides, suggest that epitopes from BBK07 could 
be developed into a sensitive and specific serodiagnostic marker for LD.  
 
 
Portions of this chapter have been published previously: 
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Chapter 6: Conclusions 
 
B. burgdorferi is a unique pathogen, able to adapt and persist in both mammal and 
arthropod hosts.  Many abilities of this spirochete are poorly understood, and since the 
vast majority of B. burgdorferi proteins have little similarity among well-studied 
proteins, the function of most gene products and the exact mechanisms of bacterial 
persistence have been difficult to elucidate.  B. burgdorferi is a clinically important 
pathogen, causing an emerging infectious disease known as Lyme disease, or Lyme 
borreliosis.  If not promptly treated, B. burgdorferi infection can lead to chronic arthritis, 
carditis, and neurological pathologies that are sometimes resistant to antibiotic treatment.  
The identification and characterization of important gene products of B. burgdorferi 
could result in improved diagnostic or therapeutic approaches to Lyme disease, as well as 
a greater understanding of this mysterious and highly evolved pathogen. 
 
I hypothesized that the in vivo-expressed surface proteins of B. burgdorferi 
contributed to persistence and virulence through interactions with the host environment.  
By analyzing the B. burgdorferi transcriptome in vivo, I mapped the transcriptional 
profiles of a selected set of genes encoding predicted surface proteins.  Of those 
expressed highly in a mammalian host, I selected two lipoproteins, BbCRASP-2 and 
BBK07, for further study.  Though previous research had suggested a role for BbCRASP-




resistance in vitro or infectivity in vivo.  I also showed that the surface lipoprotein 
BBK07 was not required for infectivity, and that BBK07 immunization did not protect 
the host from infection or disease.  Together, these results suggest that the surface 
proteins of B. burgdorferi may work together in functionally redundant families.  While 
these lipoproteins may confer an evolutionary advantage over a longer time scale, they 
can be partially compensated for, resulting in a phenotype too subtle to detect in the 
laboratory mouse model.  Finally, I showed that BBK07 is an immunodominant antigen 
of B. burgdorferi, and that BBK07-based diagnostics have the potential to improve 




While I was unable to find a phenotype in the gene-deletion mutants I generated, 
the functions of BbCRASP-2 and BBK07 remain an enigma.  My transcriptional analysis 
can be used and extended to select other possible surface proteins for similar mutagenesis 
experiments.  Whole-genome transposon mutagenesis could significantly speed the rate 
at which genes can be characterized in this way.  B. burgdorferi is highly evolved to 
persist in mammals for years, one of the few extracellular bacteria capable of this feat.  
This unique ability combined with the plethora of B. burgdorferi outer surface proteins 
suggests that functional proteins are present on the surface of the bacterium.  Once 
identified, the mechanisms and host ligands can be identified, providing information 
about B. burgdorferi, as well as our own immune system, that could be applicable to 




further understand the biology of host-pathogen interactions.  These studies could lead to 
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